

# KLRG1 identifies regulatory T cells with mitochondrial alterations that accumulate with aging

Received: 19 June 2023

Accepted: 27 March 2025

Published online: 30 April 2025

 Check for updates


Gonzalo Soto-Herederó<sup>1,2</sup>, Enrique Gabandé-Rodríguez<sup>1,2</sup>, Elisa Carrasco<sup>3</sup>, José Ignacio Escrig-Larena<sup>2</sup>, Manuel M. Gómez de las Heras<sup>1</sup>, Sandra Delgado-Pulido<sup>2</sup>, Isaac Francos-Quijorna<sup>1,2</sup>, Eva M. Blanco<sup>2</sup>, Álvaro Fernández-Almeida<sup>2</sup>, David Abia<sup>2</sup>, María Josefa Rodríguez<sup>4</sup>, Cristina M. Fernández-Díaz<sup>5</sup>, María Beatriz Álvarez-Flores<sup>6</sup>, Ana Ramírez de Molina<sup>5</sup>, Sascha Jung<sup>7,8,9</sup>, Antonio del Sol<sup>7,8,9</sup>, Virginia Zorita<sup>6</sup>, Fátima Sánchez-Cabo<sup>6</sup>, Carlos Torroja<sup>6</sup> & María Mittelbrunn<sup>2</sup>✉

Recent studies using single-cell RNA sequencing technology have uncovered several subpopulations of CD4<sup>+</sup> T cells that accumulate with aging. These age-associated T cells are emerging as relevant players in the onset of inflammaging and tissue senescence. Here, based on information provided by single-cell RNA sequencing data, we present a flow cytometry panel that allows the identification of age-associated T cell subsets in systematic larger analysis in mice. We use this panel to evaluate at the single-cell level mitochondrial and senescence marks in the different age-associated CD4<sup>+</sup> T cell subpopulations. Our analysis identifies a subpopulation of regulatory T (T<sub>reg</sub>) cells that is characterized by the extracellular expression of the co-inhibitory molecule killer cell lectin-like receptor subfamily G member 1 (KLRG1) and accumulates with aging in humans and mice. KLRG1-expressing T<sub>reg</sub> cells display senescence features such as mitochondrial alterations, increased expression of cell-cycle regulators and genomic DNA damage. Functionally, KLRG1<sup>+</sup> T<sub>reg</sub> cells show a reduced suppressive activity in vivo accompanied by a pro-inflammatory phenotype.

With age, the immune system loses the ability to respond to infections, cancer or vaccination. Instead, it engages in autoimmune and pro-inflammatory responses, which favor tissue damage and the acquisition of a low-grade systemic chronic inflammation, known as inflammaging, increasing the risk of many age-related diseases<sup>1</sup>. Thus, the decline of immune function during aging represents a major clinical challenge in many disease conditions including autoimmune diseases, infectious diseases, cancer and neurodegenerative and cardiovascular disorders<sup>2–4</sup>. The use of single-cell RNA sequencing (scRNA-seq) has allowed a deeper characterization of the different subsets of CD4<sup>+</sup> T cells that accumulate during aging. CD4<sup>+</sup> age-associated T cells (TAAs)

include effector/memory T cells; a population of regulatory T (T<sub>reg</sub>) cells expressing activation genes (denoted as activated T<sub>reg</sub> cells or aT<sub>reg</sub> cells); cells with an exhaustion signature (denoted as exhausted); and cells overexpressing genes associated with cytotoxicity that have previously been described in the context of viral infections and cancer as CD4<sup>+</sup> cytotoxic T cells (denoted as cytotoxic)<sup>5</sup>.

T<sub>reg</sub> cells, a subtype of CD4<sup>+</sup> T cells characterized by the expression of the forkhead box transcription factor (FOXP3), are required to maintain immune homeostasis and avoid excessive tissue damage preventing inflammatory and autoimmune diseases<sup>6</sup>. Understanding the molecular mechanisms behind age-associated changes



**Fig. 1 | CD4<sup>+</sup> T cells progressively accumulate altered mitochondria during aging.** **a, b,** Representative flow cytometry plots showing the simultaneous analysis of MtG and MitoTracker Red CMXRos (a) and the percentage of cells with MtG<sup>hi</sup>MtDR<sup>hi</sup>, MtG<sup>hi</sup>MtDR<sup>lo</sup> and MtG<sup>lo</sup>MtDR<sup>lo</sup> (b) in the circulating CD4<sup>+</sup> T cells from 2-month-old ( $n = 5$ ), 9-month-old ( $n = 5$ ), 13-month-old ( $n = 5$ ), 17-month-old ( $n = 5$ ) and 21-month-old ( $n = 6$ ) mice. **c, d,** Representative flow cytometry plots (c) and quantifications (d) of the simultaneous analysis of MtG and MitoTracker Red CMXRos in splenic CD4<sup>+</sup> T cells from young (2-month-old) and aged (21-month-old) mice. **e,** Representative flow cytometry plots showing the sorting strategy of MtG<sup>hi</sup>MtDR<sup>hi</sup> and MtG<sup>lo</sup>MtDR<sup>lo</sup> CD4<sup>+</sup> T cells from old mice. **f, g,** Representative images of electron microscopy (f) and quantifications (g) of healthy and morphologically altered mitochondria in MtG<sup>hi</sup>MtDR<sup>hi</sup> (green) and MtG<sup>lo</sup>MtDR<sup>lo</sup>

(red) splenic CD4<sup>+</sup> T cells from old mice ( $n = 90$  and 300 cells from 2 different mice). **h, i,** Representative flow cytometry plots (h) and quantifications (i) of MtG<sup>hi</sup>MtDR<sup>hi</sup> and MtG<sup>lo</sup>MtDR<sup>lo</sup> cells in circulating naive (CD62L<sup>hi</sup>CD44<sup>lo</sup>, blue) and effector (CD62L<sup>lo</sup>CD44<sup>hi</sup>, purple) CD4<sup>+</sup> T cells from 2-, 9-, 13-, 17- and 21-month-old mice ( $n = 6$  mice per group). Each dot represents an individual mouse. Data are presented as mean values  $\pm$  s.e.m. Statistical analysis was performed using one-way ANOVA with post hoc Tukey's correction (b), two-tailed unpaired Student's *t*-test (d and i: MtDR<sup>hi</sup>MtG<sup>hi</sup> 2 months, 9 months, 17 months, 21 months; MtDR<sup>lo</sup>MtG<sup>lo</sup> 2 months, 9 months, 21 months), two-tailed Welch's *t*-test (i: MtDR<sup>hi</sup>MtG<sup>hi</sup> 13 months; MtDR<sup>lo</sup>MtG<sup>lo</sup> 13 months, 17 months) or Mann-Whitney *U* test (g). \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ ; \*\*\*\* $P < 0.0001$ . Exact *P* values and additional statistical parameters can be found in the source data.

in the T<sub>reg</sub> compartment is critical to understand the deterioration of the immune system during aging and the consequences for immunosenescence and inflammaging. T<sub>reg</sub> cells in aged mice are augmented in lymphoid organs (for example, spleen and lymph nodes)<sup>7–9</sup> and other nonlymphoid tissues such as the visceral fat and lungs<sup>10</sup>, whereas they are reduced in muscle<sup>11</sup>. T<sub>reg</sub> cells also undergo molecular changes with aging, becoming more dependent on IL-15 signaling owing to a lower expression of the IL-2 receptor CD25, while exhibiting enhanced levels of CD122 (IL-2/IL-15 receptor chain  $\beta$ )<sup>12,13</sup>. Moreover, they acquire a memory-like profile during aging, characterized by the downregulation of CD62L and the upregulation of CD44 and CD69 (refs. 14,15). These aged effector–memory T<sub>reg</sub> cells display increased expression of canonical pro-inflammatory transcription

factors such as T-BET and ROR $\gamma$ T, and pro-inflammatory cytokines such as IFN- $\gamma$  or IL-17A<sup>16</sup>. T<sub>reg</sub> cells with pro-inflammatory phenotypes have been denoted as fragile T<sub>reg</sub> cells in the context of cancer, although its function in antitumoral responses is still debated<sup>17,18</sup>.

Killer cell lectin-like receptor subfamily G, member 1 (KLRG1) is a co-inhibitory receptor expressed by natural killer (NK) cells and antigen-experienced T cells. The expression of KLRG1 increases dramatically with age in human blood samples<sup>19</sup>. In mice, KLRG1 has been used to identify memory precursor cells from effector T cells. In acute viral infection models, KLRG1 distinguishes short-lived effector CD8<sup>+</sup> T cells (KLRG1<sup>hi</sup>) and memory precursor effector CD8<sup>+</sup> T cells (KLRG1<sup>lo</sup>)<sup>20,21</sup>. Importantly, KLRG1 identifies senescent CD8<sup>+</sup> T cells in humans and mice, as KLRG1<sup>hi</sup>CD8<sup>+</sup> T cells exhibit reduced cytokine

production and senescence characteristics such as a reduced proliferative capacity<sup>19,22–24</sup>. Regarding CD4<sup>+</sup> T cells, KLRG1 also identifies terminally differentiated cells<sup>25</sup>. Specifically in T<sub>reg</sub> cells, KLRG1 is considered a marker of effector suppressive T<sub>reg</sub> cells that display increased levels of activation markers (CD69, CD44, CD103 and CD39) and enhanced production of IL-10 (ref. 26).

Mitochondria are the key controller of cellular metabolism, but also play a crucial role as signaling hubs for inflammation and cell death. Mitochondrial function declines with age in different cell types and tissues<sup>27</sup>, including T cells<sup>28,29</sup>, affecting the mitochondrial ATP generation as well as reactive oxygen species (ROS) production and cellular signaling<sup>30</sup>. In addition, mitochondrial dysfunction is sufficient to drive cellular senescence in fibroblasts<sup>31,32</sup>. In contrast to conventional T cells, which engage glycolysis during immune response, T<sub>reg</sub> cells preferentially use mitochondrial respiration as source of ATP<sup>33</sup> and the genetic induction of T<sub>reg</sub>-specific mitochondrial dysfunction leads to premature death by uncontrolled inflammation<sup>34,35</sup>. Here, by using multiparametric spectral flow cytometry, we investigate the specific subpopulations of T cells that accumulate mitochondrial alterations during aging. Among them, we identify a population of T<sub>reg</sub> cells characterized by the expression of KLRG1 (kT<sub>reg</sub> cells) and FOXP3 that displays senescence features such as nuclear DNA damage. Although the suppressive capacity of kT<sub>reg</sub> cells is maintained in vitro, it is compromised in vivo. kT<sub>reg</sub> cells produce pro-inflammatory cytokines and, importantly, are also increased among human peripheral blood mononuclear cells (PBMCs) with age.

## Results

### T cells with mitochondrial alterations accumulate with aging

To investigate age-associated mitochondrial dysfunction in T cells, we examined mitochondrial mass and mitochondrial membrane potential (MMP) by flow cytometry in circulating CD4<sup>+</sup> T cells from C57BL/6 mice at different ages ranging from 2 to 21 months old by combining MitoTracker Green (MtG) and MitoTracker DeepRed (MtDR) staining. As a control, we used oligomycin that, by inhibiting the proton ATPase, increased the MMP and therefore the MtDR signal (Extended Data Fig. 1a). Both the MtG and MtDR signals declined during aging in circulating CD4<sup>+</sup> T cells (Extended Data Fig. 1b,c), suggesting that the proportion of T cells with mitochondrial alterations increases in aged mice (Fig. 1a,b). We obtained similar results using two additional mitochondrial probes: MitoTracker Red CM-X-ROS (Fig. 1c,d) and tetramethylrhodamine methyl ester (TMRM) (Extended Data Fig. 1d). Interestingly, MtG<sup>lo</sup>MtDR<sup>lo</sup> cells, which accumulate with aging, showed a reduced MtDR/MtG ratio, suggesting mitochondrial defects (Extended Data Fig. 1e). To confirm that MtG<sup>lo</sup>MtDR<sup>lo</sup> cells have altered mitochondria, we sorted MtG<sup>hi</sup>MtDR<sup>hi</sup> and MtG<sup>lo</sup>MtDR<sup>lo</sup> CD4<sup>+</sup> T cells from aged mice and performed electron microscopy (Fig. 1e,f). MtG<sup>lo</sup>MtDR<sup>lo</sup> cells showed an increased percentage of mitochondria with altered morphology<sup>36</sup> identified as round, small and with unstructured or even lost mitochondria cristae (Fig. 1f,g).

Because the T cell subsets dramatically change with age and the most notable changes are the loss of naive T cell subsets and the

increase in the effector memory pool<sup>37</sup>, we assessed mitochondrial probes in naive (CD62L<sup>hi</sup>CD44<sup>lo</sup>) and effector–memory (CD62L<sup>lo</sup>CD44<sup>hi</sup>) CD4<sup>+</sup> T cells in mice at different ages. We observed that, even in old mice, naive T cells were MtG<sup>hi</sup>MtDR<sup>hi</sup>, while effector–memory cells were characterized by MtG<sup>lo</sup>MtDR<sup>lo</sup>, even in younger mice (Fig. 1h,i).

### KLRG1 identifies age-associated regulatory T cells

To assess whether age-associated mitochondrial dysfunction equally affects all TAA subsets, we developed a multiparametric staining panel to identify the different age-associated CD4<sup>+</sup> T cell subsets. Our panel included surface markers based on gene expression of surface proteins identified by scRNA-seq<sup>5,38</sup>, complemented with known markers for immunosenescence, such as KLRG1 (ref. 19). In previous scRNA-seq experiments, splenic T cells from young mice were mainly classified as naive, naive\_ISG15 and rT<sub>reg</sub> cells, whereas T cells from old mice were characterized by the accumulation of TAAs such as aT<sub>reg</sub>, effector memory T (T<sub>EM</sub>) cells, exhausted and cytotoxic T cells<sup>5</sup>. Unbiased clusterization of spectral flow cytometry analysis of splenic CD4<sup>+</sup> T cells from young (2-month-old) and old (21-month-old) mice resulted in seven subpopulations of T cells (Fig. 2a,b). Naive T cells were characterized by the expression of the adhesion molecule CD62L and the absence of the activation marker CD44. Three subsets of T<sub>reg</sub> cells were identified by the expression of CD25 and discriminated by different expression levels of CD62L, CD44 and KLRG1. The other CD4<sup>+</sup> T cell clusters presented marks of differentiation (CD62L<sup>lo</sup> and CD44<sup>hi</sup>) and were identified as cytotoxic based on the expression of NK-like markers, such as NKG2A and NKG2D, or as exhausted, based on the expression of classical exhaustion markers such as PD-1 and TIM3 (Fig. 2c,d). Young mice mostly displayed naive and rT<sub>reg</sub> cells, while aT<sub>reg</sub>, kT<sub>reg</sub>, T<sub>EM</sub>, cytotoxic and exhausted cells were increased in spleen from old mice (Fig. 2e,f). Importantly, this panel discriminated six out of the seven subpopulations previously defined by scRNA-seq analyses; however, because the panel is based on surface markers, we could not identify the ISG15\_naive T cell subpopulation (Extended Data Fig. 2a,b). Our analysis identified a TAA subset characterized by the expression of KLRG1 (Fig. 2b and Extended Data Fig. 2a,b). In fact, circulating KLRG1<sup>+</sup> CD4<sup>+</sup> T cells progressively accumulated with aging (Extended Data Fig. 2c). Notably, these cells co-expressed KLRG1 and CD25, suggesting that KLRG1<sup>+</sup> CD4<sup>+</sup> T cells are probably a subpopulation of T<sub>reg</sub> cells (Fig. 2c,d). To confirm whether these CD25<sup>+</sup> KLRG1<sup>+</sup> cells were T<sub>reg</sub> cells, we combined the panel with the intracellular marker FOXP3 and we found that most of KLRG1<sup>+</sup> cells expressed CD25 and FOXP3 (83–87%) (denoted as kT<sub>reg</sub> cells), supporting their T<sub>reg</sub> identity (Fig. 2g). The percentages of splenic kT<sub>reg</sub> cells assessed by spectral flow cytometry gradually increased with age within both the T<sub>reg</sub> compartment and CD4<sup>+</sup> T cells (Extended Data Fig. 2d,e).

In addition, we reanalyzed existing and publicly available scRNA-seq data from young and old mice to separate the novel kT<sub>reg</sub> cluster<sup>5</sup>. By increasing the depth of the clusterization, we obtained an additional cluster, which accumulated during aging, within the aT<sub>reg</sub> subset (Extended Data Fig. 3a,b). Interestingly, the most determinant genes of this cluster were reminiscent of kT<sub>reg</sub> cells (Supplementary Table 1). These cells showed increased gene expression of *Klrg1* and altered expression of genes related to T<sub>reg</sub> function compared with


**Fig. 2 | Multiparametric spectral flow cytometry identifies a new age-associated T<sub>reg</sub> subset.** **a**, UMAP representation of splenic CD4<sup>+</sup> T cells from young (left) and old mice (right) analyzed by spectral flow cytometry. **b**, UMAP with Cluster-X overlay showing the distribution of the different clusters of CD4<sup>+</sup> T cells identified by spectral flow cytometry ( $n = 4$  mice per group). **c**, UMAP representation of the expression levels of representative markers used to identify TAAs by flow cytometry. **d**, The distribution of the gMFI of representative markers used to identify TAAs in CD4<sup>+</sup> T cell subpopulations: naive (blue), rT<sub>reg</sub> (yellow), aT<sub>reg</sub> (orange), kT<sub>reg</sub> (red), T<sub>EM</sub> (light green), cytotoxic (brown) and exhausted (dark green) ( $n = 4$  mice per group). **e**, **f**, Representative pie charts (**e**) and box

plots (**f**) comparing the percentage of cells belonging to each T cell subset in young (2-month-old,  $n = 4$ ) and old (22-month-old,  $n = 5$ ) mice. **g**, The gating strategy to identify FOXP3<sup>+</sup> cells within the kT<sub>reg</sub> cells in young (2-month-old) and old (22-month-old) mice ( $n = 3$  per group). gMFI, geometric mean fluorescence intensity. Each dot represents an individual mouse. Box-and-whisker plots show the median, the maximum, the minimum and the 25th and 75th percentiles. Statistical analysis was performed using two-tailed unpaired Student's *t*-test (**f**: naive) or two-tailed unpaired Welch's *t*-test (**f**: rT<sub>reg</sub>, aT<sub>reg</sub>, kT<sub>reg</sub>, T<sub>EM</sub>, exhausted and cytotoxic). \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ . Exact *P* values and additional statistical parameters can be found in the source data.




aT<sub>reg</sub> cells, such as *Icos* and *Maf* (Extended Data Fig. 3c). We also found that kT<sub>reg</sub> cells expressed higher levels of inflammatory genes such as those belonging to the *s100a* family (including *S100a4*, *S100a6*, *S100a10*, *S100a11* and *S100a13*) and inflammation-related proteins such as galectins (*Lgals1* and *Lgals9*), IL-18 receptor (*Il18r*) and IFN- $\gamma$  receptor (*Ifngr1*) (Extended Data Fig. 3d).

Then, we investigated the tissue distribution of kT<sub>reg</sub> cells. To map their preferential location in the different tissues, we used the multiparametric flow cytometry panel to analyze T cells from different tissues including spleen, bone marrow, liver, colonic lamina propria, white adipose tissue and Peyer's patches from young and old mice. kT<sub>reg</sub> cells were found in all these tissues (Fig. 3a), and interestingly,








**Fig. 3 | kT<sub>reg</sub> cells accumulate peripheral tissues during aging and are preferentially located in the colonic lamina propria.** **a**, UMAP with Cluster-X overlay showing the distribution of the different clusters of CD4<sup>+</sup> T cells from spleen, bone marrow, liver and colonic lamina propria of young mice analyzed by spectral flow cytometry. **b**, UMAP with Cluster-X overlay showing the distribution of the different clusters of CD4<sup>+</sup> T cells from young mice in different tissues ( $n = 5$ ). **c**, Representative bar plots showing the percentage of cells belonging to each T cell subset in spleen, bone marrow, liver and colonic lamina propria from young mice ( $n = 5$ ). **d, e**, Quantifications of absolute numbers of kT<sub>reg</sub> cells (**d**)

and the percentage of kT<sub>reg</sub> cells among T<sub>reg</sub> cells (**e**) in different tissues in young (2-month-old,  $n = 5$ ) and old (22-month-old,  $n = 4$ ) mice. WAT, white adipose tissue. Box-and-whisker plots show the median, the maximum, the minimum and the 25th and 75th percentiles. Statistical analysis was performed using two-tailed unpaired Student's *t*-test (**d**: spleen and WAT; **e**: bone marrow, liver, lamina propria and Peyer's patches) or two-tailed Welch's *t*-test (**d**: bone marrow, lamina propria and Peyer's patches; **e**: spleen and Peyer's patches). \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ . Exact *P* values and additional statistical parameters can be found in the source data.



**Fig. 4 | TAAs have different predisposition to mitochondrial perturbations.**

**a**, Representative flow cytometry plots showing the simultaneous analysis of MtG and MtDR in the different subsets of CD4<sup>+</sup> T cells from 2- and 21-month-old mice: naive (blue), rT<sub>reg</sub> cells (yellow), aT<sub>reg</sub> cells (orange), kT<sub>reg</sub> cells (red), T<sub>EM</sub> (light green), cytotoxic (brown) and exhausted (dark green) ( $n = 6$  mice per group). **b**, A comparison of the percentage of MtG<sup>lo</sup>MtDR<sup>lo</sup> cells in each cluster of CD4<sup>+</sup> T cells in young (2-month-old) and old (21-month-old) mice ( $n = 6$  mice per group). **c**, A statistical comparison of the percentage of MtG<sup>lo</sup>MtDR<sup>lo</sup> cells

in the different clusters in young or old mice ( $n = 6$  mice per group). Each dot represents an individual mouse. Data are presented as mean values  $\pm$  s.e.m. Box-and-whisker plots show the median, the maximum, the minimum and the 25th and 75th percentiles. Statistical analysis was performed using two-tailed unpaired Student's *t*-test (**b**: naive, rT<sub>reg</sub>, aT<sub>reg</sub> and T<sub>EM</sub>), Mann-Whitney *U* test (**b**: kT<sub>reg</sub> and exhausted) or Friedman test with post hoc Dunn's correction (**c**). n.s., not significant; \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ . Exact *P* values and additional statistical parameters can be found in the source data.

the highest percentage of kT<sub>reg</sub> cells was observed in the colonic lamina propria (Fig. 3b,c). Importantly, the absolute numbers and the percentage of kT<sub>reg</sub> cells were increased in different tissues during aging (Fig. 3d) and their percentage was increased in spleen, bone marrow, liver and Peyer's patches but not in lamina propria and white adipose tissue (Fig. 3e). Altogether, we have developed a multiparametric flow cytometry method that allows the identification of TAA subsets in both lymphoid and nonlymphoid organs. Using this strategy, we have identified a subset of T<sub>reg</sub> cells characterized by the expression of KLRG1 that accumulates with aging.


#### KLRG1<sup>+</sup> T<sub>reg</sub> cells show mitochondrial alteration and senescence features

To evaluate if any of the CD4<sup>+</sup> T cell subsets are more susceptible to the age-associated mitochondrial dysfunction, we combined our spectral flow cytometry panel together with the assessment of mitochondrial probes in young and old mice. Old CD4<sup>+</sup> T cells showed an increased proportion of MtG<sup>lo</sup>MtDR<sup>lo</sup> cells in all subsets compared with young CD4<sup>+</sup> T cells (Fig. 4a,b). Strikingly, even within the same mouse, there is a remarkable difference in the percentage of MtG<sup>lo</sup>MtDR<sup>lo</sup> in the distinct T cell subsets. While the naive cluster mainly exhibits low frequencies of MtG<sup>lo</sup>MtDR<sup>lo</sup> cells, T<sub>EM</sub> cells displayed the major accumulation of MtG<sup>lo</sup>MtDR<sup>lo</sup> cells in both young and old mice. Among T<sub>reg</sub> cells, kT<sub>reg</sub> cells showed an increased percentage of MtG<sup>lo</sup>MtDR<sup>lo</sup> cells compared with other T<sub>reg</sub> subsets in both young and old mice (Fig. 4a,c),

suggesting that kT<sub>reg</sub> cells are terminally differentiated T<sub>reg</sub> cells with mitochondrial alterations.

To better characterize the different T<sub>reg</sub> subpopulations, we compared the transcriptomic fingerprint of rT<sub>reg</sub>, aT<sub>reg</sub> and kT<sub>reg</sub> cells isolated from young (2-month-old) and old (26-month-old) mice by bulk RNA-seq. This transcriptomic dataset allowed us to improve the resolution of the kT<sub>reg</sub> cell expression profile. The clusterization grouped the samples by their identity rather than the age of the mice (Fig. 5a,b). We then analyzed the differentially expressed genes between the two age-associated T<sub>reg</sub> subsets, aT<sub>reg</sub> and kT<sub>reg</sub>. We found *Klrg1*, *Il1rl1* and *Cd200r1* as the most significantly increased genes in kT<sub>reg</sub> cells. Other genes upregulated in kT<sub>reg</sub> cells included *Foxp3*, *Gata3*, *Ahr*, NK-related genes (*Klra8*), granzymes (*Gzmb*, *Gzma* and *Gzmc*) and chemokine receptors (*Ccr3* and *Ccr10*) (Fig. 5c). The pathway analysis showed that kT<sub>reg</sub> cells exhibit increased expression of cellular senescence genes and P53 target genes, decreased expression of genes related to mitochondrial function and increased expression of inflammatory genes (Fig. 5d).


Given that a mitochondrial dysfunction is a trigger of cellular senescence<sup>31</sup>, and that the transcriptional fingerprint of kT<sub>reg</sub> cells showed increased expression of senescence-related genes, we interrogated whether kT<sub>reg</sub> cells display other features of cellular senescence beyond mitochondrial alterations. We analyzed the expression of the cell cycle regulators P16 and P21, which are increased in CD4<sup>+</sup> T cells during aging (Fig. 5e,f). We compared the three different subsets of



**Fig. 5 | KLRG1 identifies T<sub>reg</sub> cells with senescence features. a–d**, RNA sequencing of rT<sub>reg</sub>, aT<sub>reg</sub> and kT<sub>reg</sub> cells from young and old mice: PCA (**a**) and clusterization (**b**); volcano plot showing the DEGs between aT<sub>reg</sub> cells and kT<sub>reg</sub> cells (**c**); heat map of selected DEGs illustrating genes characteristic of identity, cellular senescence, P53 signaling, mitochondrial function and inflammation (**d**) ( $n = 4$  per group). **e, f**, Quantification of the expression of P16 (**e**) and P21 (**f**) by flow cytometry in splenic CD4<sup>+</sup> T cells from young (2 months old,  $n = 4$ ) and old (21 months old,  $n = 3$ ) mice measured as gMFI. **g, h**, Representative histograms and quantifications of the expression of P16 (**g**) and P21 (**h**) by flow cytometry in the different subsets of splenic T<sub>reg</sub> cells from young ( $n = 4$ ) and old ( $n = 3$ ) mice measured as gMFI: rT<sub>reg</sub> cells (yellow), aT<sub>reg</sub> cells (orange) and kT<sub>reg</sub> cells (red). **i**, Quantification of γH2AX gMFI in CD4<sup>+</sup> T cells from young and old mice ( $n = 5$  per group). **j**, Representative histogram and quantification of γH2AX by flow

cytometry in the different subsets of T<sub>reg</sub> cells from young and old mice measured as gMFI ( $n = 5$  per group). gMFI values are relative to the gMFI in naive CD4<sup>+</sup> T cells. DEGs, differentially expressed genes; gMFI, geometric mean fluorescence intensity. Each dot represents an individual mouse. Data are presented as mean values  $\pm$  s.e.m. Statistical analysis between young and old mice was performed using two-tailed unpaired Student's *t*-test (**e–h**: aT<sub>reg</sub>; **i** and **j**) or two-tailed Welch's *t*-test (**h**: rT<sub>reg</sub> and kT<sub>reg</sub>). Statistical analysis between subsets within the same animal was performed using RM one-way ANOVA with post hoc Tukey's correction (**g, h** and **j**). Asterisks refers to statistic comparisons between rT<sub>reg</sub>, aT<sub>reg</sub> and kT<sub>reg</sub> in the same age group; the number signs refer to statistic comparisons between young and old mice. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ . Exact *P* values and additional statistical parameters can be found in the source data.





**Fig. 6 | KLRG1<sup>+</sup> T<sub>reg</sub> differentiation depends on the IL-33–ST2 axis.**

**a**, Representative histograms and quantifications of the expression of different transcription factors by flow cytometry in splenic  $rT_{reg}$  (yellow),  $aT_{reg}$  (orange) and  $kT_{reg}$  (red) cells from old (21-month-old) mice measured as gMFI ( $n = 6$  mice per group). gMFI values are relative to the MFI in  $rT_{reg}$  cells ( $n = 6$  per group). **b**, Representative histograms and quantifications of ST2 expression by flow cytometry in the different clusters of splenic  $CD4^+$  T cells from young (2-month-old) and old (21-month-old) mice: naive (blue),  $rT_{reg}$  (yellow),  $aT_{reg}$  (orange),  $kT_{reg}$  (red),  $T_{reg}$  (light green), cytotoxic (brown) and exhausted (dark green) cells measured as gMFI ( $n = 6$  mice per group). **c–g**, In vivo differentiation of  $kT_{reg}$  cells: young control mice (2 months old) were treated with IL-2 + IL-33 or NaCl for 6 days and analyzed on day 7 after injection ( $n = 3$  mice per group) (**c**); representative flow cytometry plot and quantification of the proportion of splenic  $T_{reg}$  cells in young mice treated with NaCl or IL-2 and IL-33 (**d**); representative flow cytometry

plot and quantification of the proportion of  $KLRG1^+$   $T_{reg}$  cells in young mice treated with NaCl or IL-2 and IL-33 (**e**); quantification of the absolute numbers of  $KLRG1^+$   $T_{reg}$  cells in young mice treated or not treated with IL-2 and IL-33 ( $n = 3$  mice per group) (**f**); quantification of the percentage of each  $T_{reg}$  cluster in young mice treated with NaCl or IL-2 and IL-33 ( $n = 3$  mice per group) (**g**). gMFI, geometric mean fluorescence intensity. Each dot represents an individual mouse. Data are presented as mean values  $\pm$  s.e.m. Box-and-whisker plots show the median, the maximum, the minimum and the 25th and 75th percentiles. Statistical analysis was performed using Friedman test with post hoc Dunn's correction (**a** and **b**: old), RM one-way ANOVA with post hoc Tukey's correction (**b**: young), two-tailed unpaired Student's *t*-test (**d**, **e** and **g**) or two-tailed Welch's *t*-test (**f**). \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ . Exact *P* values and additional statistical parameters can be found in the source data.


$T_{reg}$  cells and found that  $kT_{reg}$  cells displayed the highest expression of P16 and P21 (Fig. 5g,h). Moreover, as an additional marker of cellular senescence, we analyzed the genomic DNA damage measured as the phosphorylation of the histone H2AX in the serine 139 ( $\gamma$ H2AX), a marker of DNA double strand breaks that is increased in  $CD4^+$  T cells from old mice (Fig. 5i). Interestingly,  $kT_{reg}$  cells also displayed increased DNA damage compared with  $aT_{reg}$  cells (Fig. 5j).

#### KLRG1<sup>+</sup> T<sub>reg</sub> cells express ST2 and are induced by IL-33 in vivo

In light of the increased expression of *Gata3* in  $kT_{reg}$  cells (Fig. 5c), and to further characterize the  $kT_{reg}$  subset, we compared the expression of different transcription factors related to T cell function by flow

cytometry. This analysis revealed that  $kT_{reg}$  cells expressed higher levels of FOXP3 compared with the other  $T_{reg}$  subsets (Fig. 6a and Extended Data Fig. 4), whereas the levels of ROR $\gamma$ T and T-BET were similar to  $aT_{reg}$  cells. Importantly,  $kT_{reg}$  cells expressed higher levels of GATA3 than  $aT_{reg}$  cells in both young and old mice (Fig. 6a and Extended Data Fig. 4), supporting the RNA-seq results. TOX and MAF expression was higher in  $kT_{reg}$  cells compared with  $rT_{reg}$  and  $aT_{reg}$  cells, but this difference was not observed in old mice (Fig. 6a and Extended Data Fig. 4).

GATA3 is essential for the regulatory function of  $T_{reg}$  cells<sup>39,40</sup>. Given that GATA3-expressing  $T_{reg}$  cells are characterized by the expression of the IL-33 receptor ST2 (refs. 41,42), we analyzed the expression of ST2 in the different  $CD4^+$  T cell clusters. We observed that  $kT_{reg}$  cells



**Fig. 7 | Analysis of the suppressive and pro-inflammatory function of KLRG1<sup>+</sup> T<sub>reg</sub> cells.** **a–f**, In vivo assessment of the suppressive activity of KLRG1<sup>+</sup> T<sub>reg</sub> cells. CD3ε<sup>-/-</sup> T cell-deficient mice were exclusively injected with naive CD45.1 CD4<sup>+</sup> T cells ( $n = 4$ ) or in combination with either CD45.2 KLRG1<sup>+</sup> T<sub>reg</sub> cells ( $n = 5$ ) or CD45.2 KLRG1<sup>+</sup> T<sub>reg</sub> cells ( $n = 5$ ) isolated from young mice treated with IL-2 + IL-33. Noninjected CD3ε<sup>-/-</sup> ( $n = 3$ ) are represented for the sake of comparison. The injected mice were monitored for 4 months and analyzed. **a**, Schematic diagram depicting the in vivo suppression assay. **b**, The body weight of CD3ε<sup>-/-</sup> mice injected with naive CD4<sup>+</sup> T cells alone or in combination with KLRG1<sup>+</sup> or KLRG1<sup>+</sup> T<sub>reg</sub> cells. The weight of each animal was normalized to its own weight before the inoculation. **c**, The percentage of transferred CD45.1 naive (striped color) or CD45.2 T<sub>reg</sub> (flat color) cells analyzed by flow cytometry in CD3ε<sup>-/-</sup> mice injected with naive and/or T<sub>reg</sub> cells. **d**, Quantification of the expression of CCL5 and PD-1 by flow cytometry in the injected CD45.1 CD4<sup>+</sup> T cells measured as gMFI. **e, f**, The percentage of mice with fibrotic colon (**e**) or fecal blood (**f**) in mice injected with naive and/or T<sub>reg</sub> cells. **g**, Representative histograms and quantifications of the


expression of different cytokines by flow cytometry in splenic rT<sub>reg</sub> (yellow), aT<sub>reg</sub> (orange) and kT<sub>reg</sub> (red) cells from old (21-month-old) mice measured as gMFI. gMFI values are relative to the MFI in rT<sub>reg</sub> cells ( $n = 6$ ). **h, i**, Analysis of the secretion of different cytokines by the T<sub>reg</sub> subsets using multiplex. T<sub>reg</sub> subsets were sorted from young mice injected with IL-2 + IL-33 and incubated during 24 h in 10% FBS complete RPMI medium before the assay ( $n = 3$ ). Heat map (**h**) and statistical comparisons of the secretion of different cytokines by rT<sub>reg</sub>, aT<sub>reg</sub> and kT<sub>reg</sub> cells. Heat map values are relative to the maximum of each cytokine. Quantification (**i**) of SASP-related cytokines secreted by rT<sub>reg</sub>, aT<sub>reg</sub> and kT<sub>reg</sub> cells. gMFI, geometric mean fluorescence intensity. Each dot represents an individual mouse. Data are presented as mean values  $\pm$  s.e.m. Statistical analysis was performed using one-way ANOVA with post hoc Tukey's correction (**c**: CD45.1; **d** and **e**), Kruskal–Wallis test with post hoc Dunn's correction (**c**: CD45.2), Friedman test with post hoc Dunn's correction (**g–i**). n.s., not significant; \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ . Exact  $P$  values and additional statistical parameters can be found in the source data.

expressed higher levels of ST2 than the rest of T cell subsets in both young and old mice (Fig. 6b). Based on that, we tried to induce the differentiation of kT<sub>reg</sub> cells in vivo by administration of IL-33 in young mice. Before IL-33 administration, we injected IL-2, which induces the expansion of T<sub>reg</sub> cells due to their expression of the IL-2 receptor CD25 (ref. 43) (Fig. 6c). Upon this treatment, we found an expansion of T<sub>reg</sub> cells in the injected mice (Fig. 6c) and an increase in the percentage and

absolute number of kT<sub>reg</sub> cells (Fig. 6e,f). Interestingly, this treatment seems to induce the differentiation of aT<sub>reg</sub> cells into kT<sub>reg</sub> cells (Fig. 6g), suggesting that kT<sub>reg</sub> cells rely on ST2–IL-33 signaling for differentiation.

### KLRG1<sup>+</sup> T<sub>reg</sub> cells exhibit a pro-inflammatory phenotype

To investigate the function of kT<sub>reg</sub> cells, we analyzed the suppressive function of these cells both in vitro and in vivo. First, we isolated T<sub>reg</sub>



**Fig. 8 | KLRG1<sup>+</sup> T<sub>reg</sub> cells are increased in human blood during aging.**

**a**, Representative flow cytometry plots of the gating of KLRG1<sup>+</sup> T<sub>reg</sub> cells in PBMCs samples from young and senior volunteers. **b–d**, Quantifications of the percentage of KLRG1<sup>+</sup> T<sub>reg</sub> cells among T<sub>reg</sub> cells (**b**), among CD4<sup>+</sup> cells (**c**) and among total lymphocytes (**d**) in young (18–25 years old,  $n = 42$ ) and senior ( $\geq 55$  years old,  $n = 75$ ) individuals by flow cytometry. Each dot represents an individual. Data are presented as mean values  $\pm$  s.e.m. Statistical analysis was performed using two-tailed unpaired Welch's  $t$ -test (**b**) or Mann–Whitney  $U$  test (**c** and **d**). \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ . Exact  $P$  values and additional statistical parameters can be found in the source data.

cells from old mice, sorted them on the basis of KLRG1 expression and co-cultured them with naive T cells loaded with CellTrace Violet at a 1:2 ratio (1 T<sub>reg</sub>:2 naive). Both KLRG1<sup>+</sup> and KLRG1<sup>−</sup> T<sub>reg</sub> cells showed a similar suppressive capacity in vitro (Extended Data Fig. 5a,b). Next, we performed an in vivo suppression assay by injecting naive CD45.1 CD4<sup>+</sup> T cells alone or in combination with CD45.2 KLRG1<sup>−</sup> or KLRG1<sup>+</sup> T<sub>reg</sub> cells into T cell-deficient mice (CD3 $\epsilon^{-/-}$  CD45.2) (Fig. 7a). While KLRG1<sup>−</sup> T<sub>reg</sub> cells were able to restrain the weight loss induced by naive T cells, mice injected with naive T cells together with KLRG1<sup>+</sup> T<sub>reg</sub> cells lost weight to a similar extent as mice exclusively injected with naive T cells (Fig. 7b). Four months after the adoptive transfer, CD45.1 cells were more abundant in mice injected with KLRG1<sup>+</sup> T<sub>reg</sub> cells (Fig. 7c). In addition, we found that transferred CD45.1 CD4<sup>+</sup> T cells were more activated when co-transferred with KLRG1<sup>+</sup> T<sub>reg</sub> cells, as shown by their increased expression of CCL5 and PD-1, than when co-transferred with KLRG1<sup>−</sup> T<sub>reg</sub> cells (Fig. 7d). Importantly, we observed an increased prevalence of fibrotic colon and fecal blood in mice injected with naive T cells alone or together with KLRG1<sup>+</sup> T<sub>reg</sub> cells than in mice injected with naive T cells together with KLRG1<sup>−</sup> T<sub>reg</sub> cells (Fig. 7e,f). Altogether, these data suggest that the function and/or viability of KLRG1<sup>+</sup> T<sub>reg</sub> cells in vivo is compromised.

To further explore the activity of kT<sub>reg</sub> cells, we assessed their capacity to produce cytokines by ex vivo intracellular flow cytometry. We found that kT<sub>reg</sub> cells from old mice expressed higher amounts of the anti-inflammatory cytokine IL-10 than the rest of the T<sub>reg</sub> subsets (Fig. 7g). We found no differences in the production of IL-17 or IFN- $\gamma$  by kT<sub>reg</sub> cells compared with aT<sub>reg</sub> cells, but kT<sub>reg</sub> cells produced

more TNF (Fig. 7g). Similar results were observed when comparing T<sub>reg</sub> subsets from young mice (Extended Data Fig. 5c). Furthermore, we measured the cytokine secretion of the different T<sub>reg</sub> subsets. We induced kT<sub>reg</sub> expansion in vivo by IL-33 administration and sorted rT<sub>reg</sub>, aT<sub>reg</sub> and kT<sub>reg</sub> cells. After 24 h in vitro, we assessed the cytokine release by multiplex analysis of the culture media and we observed that, in agreement with our flow cytometry data, kT<sub>reg</sub> cells secreted higher amounts of IL-10 together with pro-inflammatory cytokines than the other T<sub>reg</sub> subsets (Fig. 7h). Notably, kT<sub>reg</sub> cells produced higher levels of senescence-associated secretory phenotype (SASP)-related factors including IL-1 $\beta$ , IL-6, IL-13, IFN- $\gamma$ , GM-CSF, CXCL2, CXCL1, CCL1 and CCL3 than rT<sub>reg</sub> or aT<sub>reg</sub> cells (Fig. 7i). Noteworthy, upon activation, aT<sub>reg</sub> cells secreted similar or even higher levels of most cytokines than kT<sub>reg</sub> cells. However, kT<sub>reg</sub> cells maintained increased production of IL-10, IL-6, GM-CSF and CXCL2 (Extended Data Fig. 5d,e). Finally, to investigate the function of kT<sub>reg</sub> cells in vivo, we adoptively transferred KLRG1<sup>−</sup> and KLRG1<sup>+</sup> T<sub>reg</sub> cells into CD3 $\epsilon^{-/-}$  mice (Extended Data Fig. 5f). In agreement with the increased production of pro-inflammatory cytokines, we found that mice transferred with KLRG1<sup>+</sup> T<sub>reg</sub> cells showed splenomegaly together with increased percentages of circulating neutrophils and basophils compared with noninjected or mice injected with KLRG1<sup>−</sup> T<sub>reg</sub> cells (Extended Data Fig. 5g,h).

### KLRG1<sup>+</sup> T<sub>reg</sub> cells increase in human blood samples during aging

We wondered whether the kT<sub>reg</sub> population is also increased in humans during aging. We used flow cytometry to analyze the presence of kT<sub>reg</sub> cells in PBMCs from a human cohort of 144 healthy volunteers separated into two groups: young (ranging from 18 to 25 years old) and senior (over 55 years old) (see Extended Data Fig. 6 for the gating strategy). We found an increased frequency of kTregs in the senior population (14.56% of T<sub>reg</sub> cells) compared with young individuals (6.35% of T<sub>reg</sub> cells) (Fig. 8).

Altogether, by using deep flow cytometry analysis, we have identified a subset of T<sub>reg</sub> cells characterized by the expression of KLRG1 and ST2. Besides typical T<sub>reg</sub> cytokines such as IL-10, kT<sub>reg</sub> cells produce other SASP-related cytokines and chemokines such as IL-1 $\beta$ , IL-6, IL-13, IFN- $\gamma$ , GM-CSF, CXCL2, CXCL1, CCL1 and CCL3. kT<sub>reg</sub> cells also harbor senescence features such as mitochondrial decline, expression of cell cycle inhibitors and DNA damage. These kT<sub>reg</sub> cells with senescence features are induced in response to IL-33 and accumulate with aging in different tissues, but they are especially abundant in the gut in mice. Importantly, circulating kT<sub>reg</sub> cells are increased in humans during aging.

## Discussion

T cells play a critical role in recognizing and depleting damage or infected cells and sustaining tissue homeostasis preventing inflammation and tissue deterioration<sup>21</sup>. However, like every cell type in the body, T cells undergo changes as they age, leading to diminished function and compromising tissue homeostasis. Recently, scRNA-seq technology has enabled the decoding of the heterogeneity of age-associated CD4<sup>+</sup> and CD8<sup>+</sup> T cells that accumulate over time<sup>5,38</sup>. Using this information, we have developed a multiparametric panel of 20 antibodies, which allows routine discrimination of T cell heterogeneity during aging by spectral flow cytometry. With this strategy, we have mapped the different TAAs that accumulate during aging in different tissues and we have identified KLRG1-expressing T<sub>reg</sub> cells as a subset accumulating in blood, lymphoid and nonlymphoid tissues during natural aging and harboring aging features, including mitochondrial alterations.

Functional T<sub>reg</sub> cells are essential to restore tissue homeostasis and to prevent autoimmunity and inflammation. Although it is well established that T<sub>reg</sub> cells are augmented in several organs during aging in both humans and mice, whether their function is compromised with



aging is still a matter of debate. Some authors showed that young and old  $T_{reg}$  cells have equivalent suppressive capacity<sup>44,45</sup>, whereas others showed an age-related increase in  $T_{reg}$  function linked to increased risk of malignancies and infections in older adults<sup>7,14</sup>. By contrast, there is also evidence of a deterioration of  $T_{reg}$  function during aging. Old  $T_{reg}$  cells are not able to suppress IL-17<sup>+</sup> T cells upon chronic inflammation<sup>44</sup>, failing to control hypersensitivity<sup>46</sup> and producing reduced amounts of IL-10 (ref. 47).

KLRG1 is a marker of highly differentiated T cells, and it has been considered as a marker of immunosenescence<sup>21</sup>. In addition, a subset of terminally differentiated  $T_{reg}$  cells that express KLRG1 has been identified as short-lived  $T_{reg}$  cells expressing higher levels of suppressive (that is, CTLA-4 and IL-10) but also inflammatory molecules<sup>26</sup> located in nonlymphoid barriers, metabolic tissues or at sites of inflammation<sup>9,48</sup>. For example, KLRG1<sup>+</sup>  $T_{reg}$  cells contribute to insulin resistance<sup>49</sup> and IFN- $\gamma$ - and IL-10-secreting KLRG1<sup>+</sup>  $T_{reg}$  cells also infiltrate the central nervous system during experimental autoimmune encephalomyelitis<sup>50</sup>. Using our flow cytometry panel, we mapped the presence of  $kT_{reg}$  cells in different tissues including spleen, bone marrow, liver, colonic lamina propria, white adipose tissue, Peyer's patches and blood during aging. Our results demonstrate that  $kT_{reg}$  cells increase during aging in most of the analyzed tissues and that the colonic lamina propria is a preferential location for  $kT_{reg}$  cells, reaching 50% of the total  $T_{reg}$  pool. Importantly,  $T_{reg}$  cells are critical for gut homeostasis<sup>51,52</sup>, which is essential for healthy aging.

Our results also support that  $kT_{reg}$  cells express the IL-33 receptor ST2 and that their differentiation depends on IL-33. IL-33 is an interleukin-1-like cytokine that plays a critical role in mucosal immunity, favoring Th2 differentiation<sup>53</sup>. IL-33 is increased in the adipose tissue with aging<sup>54</sup>, and it induces thymic involution and T cell dysfunction<sup>55</sup>. Further research is required to define whether IL-33 levels change in lymphoid tissues or in the circulation during aging or if the differentiation of  $kT_{reg}$  cells depends on other factors.

By combining the multiparametric panel with mitochondrial probes, we assessed which of the different T cell subsets that accumulate during aging show mitochondrial dysfunction. We found that, whereas naive T cells are MtG<sup>hi</sup>MtDR<sup>hi</sup>, even in old mice, TAAs show increased percentage of cells with low MtG and MtDR stainings. Within  $T_{reg}$  cells, we found that  $kT_{reg}$  cells show higher percentage of MtG<sup>lo</sup>MtDR<sup>lo</sup>, indicating that they harbor reduced mitochondrial mass and MMP. The MMP is an important indicator of mitochondrial integrity and function. During the mitochondrial respiration, electrons are ejected from the mitochondrial matrix to the intermembrane space to generate an electrochemical gradient. An optimal MMP is required for most of the mitochondrial functions including the generation of ATP, the uptake of ions, the synthesis of iron–sulfur clusters and others. When the MMP is not recovered, unpolarized mitochondria are degraded by mitophagy<sup>56</sup>. The simultaneous assessment of mitochondrial mass and MMP by flow cytometry have been extensively used to characterize the health status of mitochondria in different tissues, including T cells, under different conditions such as tumor environment<sup>57–60</sup>. Nevertheless, changes in the molecular composition of mitochondria, particularly in cardiolipins, lead to a reduction in the binding of MitoTracker probes in intraepithelial lymphocytes that, besides their low signal of MtG and MtDR, showed a similar mitochondrial number on electron microscopy images<sup>61</sup>. Importantly, a reduction in the staining of these probes could also be explained by changes in the plasma membrane potential or by the expression of multidrug resistance transporters that expel the fluorescent probes<sup>62</sup>. To confirm that the changes that we observed in MtG and MDR staining are related to mitochondria, we sorted MtG<sup>hi</sup>MtDR<sup>hi</sup> and MtG<sup>lo</sup>MtDR<sup>lo</sup> CD4<sup>+</sup> T cells and assessed mitochondrial morphology by electron microscopy. Electron microscopy analysis shows that MtG<sup>lo</sup>MtDR<sup>lo</sup> cells have mitochondrial changes including signs of cristae remodeling, supporting that MtG<sup>lo</sup>MtDR<sup>lo</sup> T cells have mitochondrial alterations. However,

additional research is needed to determine whether the MtG<sup>lo</sup>MtDR<sup>lo</sup> T cell population also has structural or biochemical changes in the composition of mitochondria, in the plasma membrane potential and/or in the expression of multidrug transporters that could explain the dramatic reduction in MtG and MtDR staining. Importantly, beyond the key role of mitochondrial metabolism for the suppressive function of  $T_{reg}$  cells<sup>35</sup>, a proper mitochondrial metabolism of  $T_{reg}$  cells is essential for maintaining liver homeostasis during aging. Deleting *Altre*, a long noncoding RNA found in  $T_{reg}$  cells and upregulated with aging, leads to mitochondrial dysfunction, causing liver inflammation, fibrosis and cancer in aged mice<sup>63</sup>. Therefore, the increase in  $kT_{reg}$  cells with impaired mitochondria could be detrimental with aging. However, the function of  $kT_{reg}$  cells during aging and age-associated diseases requires further exploration.

Our findings demonstrate that, besides mitochondrial alterations,  $kT_{reg}$  cells harbor other signs of senescence. A recent study found that  $T_{reg}$  cells undergo senescence faster than conventional T cells through a ROS-dependent mechanism<sup>64</sup>. In addition, both mitochondrial decline and cellular senescence are tightly interconnected<sup>31,32</sup>. An important number of senescent-associated changes are dependent on mitochondrial function, especially the pro-inflammatory phenotype. Therefore, the pro-inflammatory phenotype observed in  $kT_{reg}$  cells could be a consequence of their mitochondrial dysfunction. The mitochondrial damage leads to the release of mitochondrial DNA (mtDNA) to the cytosol. mtDNA fragments trigger the activation of the cGAS–STING pathway, leading to the production of type I interferons, such as IFN- $\beta$ , and pro-inflammatory cytokines, such as TNF or IL-6 (ref. 65), which are part of the SASP<sup>66</sup>. Cytosolic mtDNA, especially the oxidized mtDNA, also activates NLRP3 promoting the assembly of the inflammasome, a structure that leads to the activation of caspase 1, therefore leading to the release of active IL-18 and IL-1 $\beta$  by the pyroptotic cell death<sup>67</sup>. As  $kT_{reg}$  cells harbor mitochondrial damage, they could also experience a release of mtDNA that would trigger their pro-inflammatory phenotype. Moreover, the mitochondrial dysfunction also contributes to lysosomal stress favoring a pro-inflammatory phenotype in CD4<sup>+</sup> T cells<sup>68</sup>.

Surprisingly, there is recent evidence supporting the idea that senescence could be a reversible state. Chemotherapy-induced senescent cells can be released from senescence and reenter into the cell cycle<sup>69</sup>. In addition, tissue senescence can be transiently induced to promote tissue regeneration in *Hydractinia symbiolongicarpus*<sup>70</sup>. Regarding CD4<sup>+</sup> T cells, a recent study demonstrated that the expression of the senescence marker KLRG1 is transient in a subset of resident  $T_{reg}$  cells, despite their maintenance of an activated phenotype<sup>71</sup>. Because the specific ablation of mitochondria from senescent cells is sufficient to reverse many features of the senescent phenotype<sup>72</sup>, mitochondria are a promising target for interventions aimed at reducing the harmful effects of senescence in aging tissues. Interestingly, mitochondrial dysfunction in exhausted CD8<sup>+</sup> T cells can be reversed by scavenging ROS or boosting mitochondrial function with nicotinamide riboside<sup>57,73,74</sup>, suggesting that mitochondrial stress is reversible and that mitochondria could be key to restoring T cell function. Future research should clarify whether mitochondrial damage and other features of senescence are targetable in  $kT_{reg}$  cells.

Sustaining a proper function of T cells during aging is essential for healthy aging. Unraveling the changes in different T cell compartments will help to better understand the underlying mechanisms of age-associated immunological decline and, thus, to develop therapeutic interventions that enhance immunity in older adults.

## Methods

### Animal procedures

C57BL/6J HccRsd mice were purchased from Envigo or generated at the Centro de Biología Molecular Severo Ochoa (Madrid, Spain) animal facilities. All mice required for this study were bred and aged in specific-pathogen-free conditions in the animal facility of Centro

de Biología Molecular Severo Ochoa (Madrid, Spain). All mice were housed in ventilated cages within animal rooms maintained under a 12 h–12 h light–dark cycle. Animal rooms were temperature and humidity controlled. Standard diet and water were available *ad libitum*. Both male and female mice were used in this study.

All the procedures with animals were previously evaluated and approved (PROEX 287/16 and PROEX 52.1/23) by the ethics committee on animal experimentation of the CBMSO, the authorized committee of the Spanish National Research Council or the Universidad Autónoma de Madrid, and the regional government (Comunidad de Madrid). All mice were checked for any macroscopic abnormalities (according to the Jackson guide 'AGED C57BL/6J MICE FOR RESEARCH STUDIES'). Mice were used at different ages: young (less than 4 months of age), adult (4–20 months of age) and old (over 20 months of age).

CD3 $\epsilon^{-/-}$  mice (JAX stock no. 004177) were kindly provided by Prof. B. Alarcón (CBM). CD45.1 (JAX stock no. 002014) mice were kindly provided by Dr. C. Cobaleda (CBM). Both strains were in C57BL/7 background.

**IL-2 + IL-33 treatment.** The IL-2 immune complex was prepared as previously described<sup>43</sup>. In brief, 1  $\mu$ g of IL-2 (Peprotech, #1212-12) was mixed with 5  $\mu$ g of  $\alpha$ -IL-2 (BioLegend, #503706) per mouse and incubated at room temperature (RT) for 30 min. Each mouse was intraperitoneally injected for three consecutive days. As a control, mice received only 200  $\mu$ l of NaCl 0.9%. From the third day, IL-2 was combined with IL-33. 1  $\mu$ g of IL-33 (BioLegend, #580506) was injected in 200  $\mu$ l of NaCl per mouse for five consecutive days. As a control, mice received only 200  $\mu$ l of NaCl.

**Adoptive transfer of T<sub>reg</sub> cells.** For the study of the function of kT<sub>reg</sub> cells *in vivo*, KLRG1 $^{-}$  and KLRG1 $^{+}$  T<sub>reg</sub> cells (CD4 $^{+}$ CD25 $^{+}$ ) were isolated by fluorescence-activated cell sorting (FACS) from IL-33-treated mice and injected into CD3 $\epsilon^{-/-}$  young mice for three consecutive days. Approximately 8  $\times$  10<sup>5</sup> total T<sub>reg</sub> cells were injected per mouse. Mice were weighed and monitored every 3 days for 4 months after the adoptive transfer and then were euthanized and the spleens were analyzed.

### Suppression assays

For the *in vivo* suppression assays, KLRG1 $^{-}$  and KLRG1 $^{+}$  T<sub>reg</sub> cells (CD4 $^{+}$ CD25 $^{+}$ ) were isolated by FACS from IL-33-treated mice. Naive CD4 $^{+}$  T cells were purified by magnetic isolation (Stemcell Technologies, #19765) from young CD45.1 mice. A total of 6  $\times$  10<sup>5</sup> naive CD4 $^{+}$  T cells alone or in combination with 1.5  $\times$  10<sup>5</sup> KLRG1 $^{-}$  or KLRG1 $^{+}$  T<sub>reg</sub> cells were intravenously injected into CD3 $\epsilon^{-/-}$  young mice. The animals were weighed and monitored every 3 days for 4 months after the adoptive transfer and then were euthanized and the colonic lamina propria was analyzed.

For the *in vitro* suppression assays, KLRG1 $^{-}$  and KLRG1 $^{+}$  T<sub>reg</sub> cells (CD4 $^{+}$ CD25 $^{+}$ ) were isolated by FACS from old mice. Naive CD4 $^{+}$  T cells were purified by magnetic isolation from young CD45.1 mice. CD45.1 $^{+}$  naive CD4 $^{+}$  T cells were labeled with 1  $\mu$ M of CellTrace Violet (Invitrogen, C34571) in PBS for 30 min at 37 °C. A total of 2.5  $\times$  10<sup>4</sup> naive T<sub>reg</sub> cells were incubated with 1.25 T<sub>reg</sub> cells for 3 days. Cells were stimulated with Mouse T-Activator Dynabeads (Gibco, 11452D) following the manufacturer's instructions. The percentage of suppression was determined as follows: 100 – (% of proliferating cells with T<sub>reg</sub> cells)/(% of proliferating cells without T<sub>reg</sub> cells).

### Human samples

Volunteer recruitment was performed through the GENYAL Clinical Trials Platform of IMDEA Alimentación (Madrid, Spain). This study was approved by the institutional Research Ethics Committee (IMDEA Food Foundation, IMD PI-052 and IMD PI-055) and performed in accordance with the principles of research involving human subjects stated in the Declaration of Helsinki (1964). All patients were clearly informed about the study methodology and provided written informed consent.

Peripheral blood samples were collected from a total of 117 volunteers belonging to two different population groups, whose inclusion criteria were as follows:

Young healthy population ( $n = 42$ ): 14 male and 28 female healthy volunteers aged between 18 and 25 years.

Senior population ( $n = 75$ ): 28 male and 47 female volunteers over 55 years of age.

Exclusion criteria were common for both study groups and included: decreased cognitive function, pregnancy or breastfeeding, severe chronic health conditions (for example, chronic kidney, liver and heart disease), immunodeficiencies and autoimmune diseases, and immunosuppressive or psychotropic pharmacological treatment. The results shown in the study apply to both sexes. The experimental groups have been defined by the age or the participants, and no sex- and gender-based analyses have been performed. Volunteers received financial compensation after the study.

### Tissue processing for flow cytometry

Mice were euthanized with CO<sub>2</sub> followed by perfusion with cold PBS. The indicated tissues were extracted and processed as specified.

**Spleen and lymph nodes.** Lymph nodes were collected from inguinal, mesenteric, cervical and axillar areas. Spleen and lymph nodes were mashed and filtered through a 70- $\mu$ m cell strainer. The cell suspension was centrifuged at 300g for 5 min at 4 °C. Red blood cells were removed using 5 ml of erythrocyte lysis buffer (ammonium chloride 0.15 M, sodium bicarbonate 0.01 M and EDTA 0.0001 M) for 5 min. Cells were washed, centrifuged, resuspended and counted.

**Blood.** Blood was extracted from either the facial vein or the heart in living or euthanized mice, respectively. The cell suspension was centrifuged at 300g for 5 min at 4 °C. Red blood cells were removed resuspending the cells in 5 ml of erythrocyte lysis buffer for 5 min. Cells were washed, centrifuged, resuspended and stained.

**Colonic lamina propria.** T cells from colonic lamina propria were isolated as previously reported<sup>75</sup>. Colon samples between the cecum and rectum were obtained and cleaned from fat and feces. Tissues were cut longitudinally, washed with cold PBS and then cut transversally into 1-cm-long fragments, mixed in prewarmed 5 mM EDTA, 14 mM HEPES, 10% FBS PBS and incubated under shaking at 180 rpm for 30 min at 37 °C. After washing with PBS, tissue pieces were then minced and mixed in prewarmed 25 mM HEPES, 10% FBS RPMI supplemented with 300 U ml<sup>-1</sup> collagenase type VIII (Sigma, C2139) under shaking at 180 rpm for 45 min at 37 °C. The digested tissue was filtered through a 70- $\mu$ m cell strainer, washed with 5 mM EDTA, 14 mM HEPES, 10% FBS PBS and centrifuged at 650g for 5 min at RT. To further enrich in leukocytes, supernatants were centrifuged in a 40%/70% Percoll gradient (Sigma, GE17-0891-01) at 750g for 20 min at RT with minimum acceleration and without brake. Isolated cells were washed with PBS and resuspended in 2% FBS RPMI for counting.

**White adipose tissue.** Gonadal white adipose tissue was obtained from the mouse abdominal cavity and mixed in 2 mg ml<sup>-1</sup> BSA, 2% FBS RPMI supplemented with 2 mg ml<sup>-1</sup> collagenase type II (Sigma, C6885) under shaking at 180 rpm for 40 min at 37 °C. The digested tissue was vertically rested to separate fat from the aqueous phases, which were obtained using an 18 G syringe. Then, the cell suspensions were filtered through a 70- $\mu$ m cell strainer and washed with 2% FBS RPMI. Finally, erythrocytes were removed by incubation with a lysis buffer for 5 min at 4 °C, washed with 1 mM EDTA PBS and finally resuspended in 1 ml of 1 mM EDTA 2% FBS PBS for counting.

**Peyer’s patches.** Peyer’s patches were collected from the intestine and mashed into a 70-µm cell strainer. The cell suspension was centrifuged at 400g for 5 min at 4 °C. Finally, the cell pellets were resuspended in 1 ml of 2% FBS RPMI for counting.

**Liver.** Liver was collected and cut into prewarmed 25 mM HEPES, 10% FBS RPMI supplemented with 0.4 mg ml<sup>-1</sup> collagenase type VIII (Sigma, C2139) under shaking at 180 rpm for 45 min at 37 °C. Digested tissue was filtered through a 70-µm cell strainer and centrifuged at 350g for 5 min at 4 °C. Red blood cells were removed using 5 ml of erythrocyte lysis buffer for 5 min. To further enrich in leukocytes, supernatants were centrifuged in a 40%/70% Percoll gradient (Sigma, GE17-0891-01) at 1,250g for 30 min at RT with acceleration on 6 and without brake. Isolated cells were washed with PBS and resuspended in ml 2% FBS RPMI for counting.

**Bone marrow.** Femurs and tibias were collected and the cells from the bone marrow were obtained by centrifuging the bones at 6,000g for 1 min. Red blood cells were removed using 5 ml of erythrocyte lysis buffer for 5 min. Cells were washed and resuspended in 2% FBS PBS for counting.

**Human samples.** Human blood samples were collected by venipuncture in an overnight fasting state. Three milliliters of blood were collected in TransFix/EDTA vacuum blood collection tubes (Cytomark) and preserved until the day of staining and cell acquisition.

Flow cytometry

To differentiate between live and dead, the cells were first stained with the Zombie NIR Fixable Viability Kit (BioLegend, 423106, 1:3,000), the Zombie Yellow Fixable Viability Kit (BioLegend, 423104, 1:3,000) or the Ghost Dye Violet 540 (Tonbo Biosciences, 13-0879, 1:3,000) for 20 min at 4 °C. Then, the cells were washed with FACS staining buffer (PBS supplemented with 2% fetal bovine serum and 1 mM EDTA) and incubated with Fc receptor blocker purified rat anti-mouse anti-CD16/CD32 (BD Biosciences, 553142, 1:200) for 20 min at 4 °C. Cells were then incubated with primary antibodies for 20 min at 4 °C and were washed twice with FACS staining buffer. The following antibodies were diluted in Brilliant Stain Buffer (BD Biosciences, 566349) for surface antigen staining:

| Antigen       | Fluorochrome    | Dilution | Clone      | Supplier       | Catalog    |
|---------------|-----------------|----------|------------|----------------|------------|
| CD38          | Pacific Blue    | 1:500    | 90         | BioLegend      | 102720     |
| TIM3          | BV480           | 1:200    | 5D12/TIM-3 | BD Biosciences | 747618     |
| CD244.2 (2B4) | BV510           | 1:200    | 2B4        | BD Biosciences | 740115     |
| CD44          | BV570           | 1:200    | IM7        | BioLegend      | 103037     |
| CD69          | BV650           | 1:100    | H1.2F3     | BioLegend      | 104541     |
| CD62L         | BV711           | 1:400    | MEL-14     | BioLegend      | 104445     |
| CD95          | BV750           | 1:100    | Jo2        | BD Biosciences | 747413     |
| KLRG1         | BV785           | 1:200    | 2F1        | BioLegend      | 138429     |
| CD223 (LAG3)  | BB515           | 1:200    | C9B7W      | BD Biosciences | 566210     |
| CD49d         | PerCP-Cy5.5     | 1:100    | R1-2       | BioLegend      | 103619     |
| PD-1          | PerCP-eFluor710 | 1:200    | J43        | ThermoFisher   | 46-9985-80 |
| ST2           | PerCP-eFluor710 | 1:200    | RMST2-33   | ThermoFisher   | 46-9333-82 |
| NKG2A         | PE              | 1:200    | 16A11      | BioLegend      | 142804     |
| NKG2D         | PE-Dazzle594    | 1:200    | CX5        | BioLegend      | 130214     |
| CD25          | PE Cy5          | 1:400    | PC61       | BioLegend      | 102007     |
| CD8           | PE-Fire700      | 1:1000   | 53-6.7     | BioLegend      | 100792     |
| CD28          | APC             | 1:50     | E18        | BioLegend      | 122016     |
| CD153         | R718            | 1:200    | RM153      | BD Biosciences | 751871     |

| Antigen | Fluorochrome | Dilution | Clone   | Supplier  | Catalog |
|---------|--------------|----------|---------|-----------|---------|
| CD27    | APC-Cy7      | 1:400    | LG.3A10 | BioLegend | 124226  |
| CD4     | APC-Fire810  | 1:1000   | Gk1.5   | BioLegend | 100480  |

For intracellular staining, after staining for membrane markers, the cells were fixed and permeabilized using the FOXP3/Transcription Factor Staining Kit (eBioscience, 00-5523-00) for 20 min at RT and darkness. To assess cytokine production, cells were stimulated for 4 h with 50 ng ml<sup>-1</sup> phorbol 12-myristate 13-acetate (PMA) (ThermoFisher, 356150010) and 1 µg ml<sup>-1</sup> ionomycin (Tocris, 1704) in the presence of brefeldin A (eBiosciences, 00-4506-51). Cells were then stained the following intracellular antibodies:

| Antibody           | Fluorochrome    | Dilution | Clone        | Supplier       | Catalog    |
|--------------------|-----------------|----------|--------------|----------------|------------|
| IL-10              | Pacific Blue    | 1:100    | JES5-16E3    | BioLegend      | 505020     |
| IL-17              | PE              | 1:100    | TC11-18H10.1 | BioLegend      | 506904     |
| TNF                | APC             | 1:100    | MP6-XT22     | BioLegend      | 506308     |
| IFN-γ              | Spark NIR 685   | 1:100    | XMG1.2       | BioLegend      | 505861     |
| MAF                | eFluor450       | 1:100    | symOF1       | ThermoFisher   | 48-9855-41 |
| FOXP3              | FITC            | 1:200    | FJK-165      | ThermoFisher   | 11-5773-82 |
| RORγt              | PE              | 1:100    | Q31-378      | BD Biosciences | 562607     |
| T-BET              | AlexaFluor594   | 1:100    | 4B10         | BioLegend      | 644834     |
| T-BET              | APC             | 1:100    | 4B10         | BioLegend      | 17-5825-82 |
| TOX                | eFluor660       | 1:200    | TXRX10       | ThermoFisher   | 50-6502-80 |
| γH2AX              | –               | 1:300    | 20E3         | CellSignaling  | 9718       |
| P16                | –               | 1:200    | Polyclonal   | ThermoFisher   | PA5-119712 |
| P21                | Alexa Fluor 647 | 1:400    | Polyclonal   | Abcam          | ab237265   |
| Donkey anti-rabbit | Alexa Fluor 647 | 1:500    | Polyclonal   | ThermoFisher   | A-31573    |

All flow cytometry experiments from mouse samples were performed with four-laser (violet, blue, yellow-green and red) or five-laser Aurora analyzers (Cytek Biosciences). Data were analyzed with the FlowJo v10.5.3 software (BD Biosciences). Gating strategies were set on the basis of fluorescence minus one controls, unstained samples and unstimulated samples (when needed). All the samples in the experiment excluded dead cells, clumps and debris.

In human samples, each tube contained at least 2 × 10<sup>6</sup> human whole blood cells. Cells were labeled by incubation with appropriate fluorescence-conjugated antibodies for 15 min at RT in the dark. Cells were then lysed with 2 ml of FACS lysing solution (BD Biosciences) for 10 min and centrifuged at 500g for 5 min at RT. Then, the cells were washed with 5 ml of PBS. The following antibodies were used for surface antigen staining:

| Antibody | Fluorochrome | Dilution | Clone      | Supplier       | Catalog |
|----------|--------------|----------|------------|----------------|---------|
| CD8      | BUV496       | 1:100    | RPA-T8     | BD Biosciences | 612942  |
| CD25     | BUV615       | 1:100    | 2A3        | BD Biosciences | 612996  |
| CD19     | BUV661       | 1:100    | 1D3        | BD Biosciences | 612971  |
| CD45     | BV510        | 1:100    | HI30       | BD Biosciences | 563204  |
| CD4      | BV786        | 1:100    | SK3        | BD Biosciences | 664528  |
| CD127    | PE           | 1:100    | HIL-7R-M21 | BD Biosciences | 561028  |
| CD3      | APC          | 1:100    | HIT3a      | BD Biosciences | 555342  |
| KLRG1    | APC-Cy7      | 1:100    | 2F1/KLRG1  | BioLegend      | 138426  |

Experiments with human samples were performed in a BD FAC-Symphony A5 SORP flow cytometer (BD Biosciences). To generate comparable results among patients and over time, the photomultiplier voltages were adjusted to unlabeled lysed whole blood cells to obtain optimal photomultiplier tube voltages for the resolution of dim cell populations. The target values resulting of the optimization



were used for subsequent calibrations to maintain instrument standardization. When possible, at least 40,000 events of CD4 population were acquired to reach the maximum  $T_{reg}$  events. Data were analyzed using the FlowJoTM v.10 software.

The gating strategy for identifying  $kT_{reg}$  cells is illustrated in the Extended Data Fig. 6. In brief, first, doublets and debris were excluded in forward scatter (FSC) – side scatter (SSC) dot plots. Then, a region in CD45 and SSC parameters were used to discriminate leukocytes. Next, lymphocytes were gated in a SSC – CD4 dot plot. Lymphoid cells were further cleaned in a SSC – CD45 plot. After that,  $CD3^+CD19^-$  T cells were gated and, among them,  $CD4^+$  T lymphocytes were distinguished. The  $T_{reg}$  cells were identified, within the  $CD4^+$  T cells, by gating the  $CD25^{hi}CD27^{lo}$  population. Then, the expression of KLRG1 was analyzed in  $T_{reg}$  cells. To have a negative control to properly gate  $KLRG1^+$  cells, the gate was established in B cells.

**Analysis of mitochondrial fitness.** Analysis of mitochondrial mass and MMP was performed by flow cytometry in cells labeled for 30 min with 50 nM MitoTracker Green FM (Invitrogen, M7514), 200 nM MitoTracker DeepRed FM (Invitrogen, M22426), 40 nM Image-iT TMRM (Invitrogen, I34361) or 50 nM MitoTracker Red CMXRos (Invitrogen, M7512) in RPMI medium with no FBS in a 37 °C and 5%  $CO_2$  incubator before extracellular staining. After incubation, cells were washed with FACS staining buffer and incubated with antibodies for extracellular staining.

#### Dimensional reduction and clustering analysis of flow cytometry data

Dimensional reduction and clustering analysis of flow cytometry data was done using OMIQ (Dotmatics). First, nonlymphocyte cells, doublets and dead cells were excluded on the basis of viability staining and FSC and SSC parameters. Then, 15,000  $CD4^+$  cells from each sample were subsampled for further analysis. For dimensional reduction, the Uniform Manifold Approximation and Projection (UMAP) algorithm was applied with the following parameters: neighbors = 15, minimum distance = 0.4, components = 2, learning rate = 1, epochs = 200. For unbiased clustering, the Cluster-X algorithm was applied with  $\alpha = 0.001$ . Mean fluorescence intensity for each marker projected on the UMAP plots was used to infer the cluster's identity, and similar clusters were combined.

#### RNA-seq

$rT_{reg}$ ,  $aT_{reg}$  and  $kT_{reg}$  cells were isolated from young and old mice by FACS. RNA was extracted with the RNeasy Micro Kit (Qiagen, 74004) following manufacturer's instructions. Sample quality was measured using the Qubit 3.0 fluorimeter for sample concentration and Agilent 5400 for fragment analysis. SMART-Seq V4 Ultra Low Input RNA kit for Sequencing 480 Rxns (TakaraBio, 634893) was used for efficient cDNA synthesis and library preparation. After amplification, cDNA was purified using AMPure XP beads (Beckman Coulter, A63882) to remove any contaminants and ensure high-quality cDNA. The library was checked with Qubit and real-time PCR for quantification and bioanalyzer for size distribution detection. Quantified libraries were pooled and sequenced on Illumina Illumina Novaseq X plus using a PE150 (pair-end 150 base pair) strategy to produce 6G of data. Fastq files quality check was performed using FastQC v0.11.9. RNA-seq reads were mapped to the *Mus musculus* reference genome, GRCm39, using Hisat2 v2.2.1 software. Reads were then preprocessed with SAMtools v1.13 to transform Sequence Alignment/Map files into Binary Alignment/Map files and sorted. The number of reads covered by each gene is calculated by HTSeq-Count v1.99.2. Downstream data analysis was performed with R v4.4.1. Analysis of differentially expressed genes was performed using DESeq2 v1.44.0. Genes with  $P < 0.05$  and  $|\log_2 \text{fold change}| > \log_2(1.5)$  were determined to show statistically significant differences in group comparison. Over-representation analysis and

gene set enrichment analysis were performed using clusterProfiler v4.12.0 package in GO, KEGG, WikiPathways, Reactome and the Hallmarks of the Molecular signatures database. Principal component analysis (PCA) plots and volcano plot were visualized using ggplot2 v3.5.1. Heat maps were visualized using heatmap v1.0.12.

#### Analysis of cytokine secretion by $T_{reg}$ subsets using Multiplex

$rT_{reg}$ ,  $aT_{reg}$  or  $kT_{reg}$  cells were isolated from IL-33-treated young mice by FACS. A total of  $5.5 \times 10^5$  cells were incubated in 200  $\mu$ l of complete RPMI medium supplemented with 10% FBS in resting conditions or in presence of Mouse T-Activator Dynabeads for 24 h. The cells were centrifuged at 300g for 5 min, and the supernatant was used for cytokine detection with magnetic bead technology (Invitrogen, Cytokine & Chemokine 26-Plex Mouse ProcartaPlex Panel 1).

#### Electron microscopy

For electron microscopy, splenocytes from old mice were labeled for 30 min with 50 nM MitoTracker Green FM and 200 nM Mitotracker DeepRed FM before extracellular staining. Cells were then labeled with a fluorochrome-conjugated antibody against CD4, and  $MtG^{hi}MtDR^{hi}$  and  $MtG^{lo}MtDR^{lo}$  alive  $CD4^+$  T cells were isolated by FACS. After sorting, cells were fixed with 4% paraformaldehyde, 2% glutaraldehyde diluted in 0.1 M phosphate buffer. Cells were postfixed with 1% osmium tetroxide and 1% potassium ferrocyanide for 60 min. After washing, incubation with 0.15% tannic acid in buffer phosphate 0.1 M for 1 min was achieved. After washing, cells were counterstained with uranyl acetate 2% for 1 h. Then, cells were dehydrated with lowering concentrations of ethanol and embedded in resin EPON. The preparations were examined with a transmission electron microscope (JEM1400 Flash, Jeol), and images were acquired with a CMOS Oneview camera (Gatan).

#### Reanalysis of scRNA-seq data

scRNA-seq data were extracted from a previously published work<sup>5</sup> and reanalyzed with the Seurat package v4.2.0 in R v4.1.3. Variable genes were identified with the FindVariableFeatures function across the range of expression values and used to perform a PCA with the RunPCA function. Clustering was performed with the FindClusters function with the Leiden algorithm and the first 20 principal components. Cluster identification was done with the FindMarkers function in each subset with a minimum log fold change of 0.25 and a  $P$  value  $< 10^{-3}$ . The  $kT_{reg}$  cluster was separated by using the FindSubCluster function in the  $aT_{reg}$  cluster and then identified with the FindMarkers function.

#### Statistics and reproducibility analysis

Unless otherwise specified,  $n$  represents the number of individual biological replicates and is represented in graphs as one dot per sample. All the data are extracted from one representative experiment ( $n \geq 3$  per group) of a minimum of two separate experiments. Flow cytometry plots are representative of at least three replicates. No statistical method was used to predetermine sample size, but a minimum of three samples were used per experimental group and condition. Data collection and analysis were not performed blind to the age of the mice.

For statistical analysis, GraphPad Prism (version 9) was used. Data are expressed as mean  $\pm$  s.e.m., unless otherwise indicated. Outliers were identified by the ROUT method (5%) and removed. Comparisons for two groups were calculated using unpaired two-tailed Student's  $t$ -tests (for two groups meeting the normal distribution criteria) or Mann–Whitney  $U$  test (for two groups without normal distribution) according to the Shapiro–Wilk normality test. When comparing different populations within the same mouse, comparisons were calculated using two-tailed paired Student's  $t$ -tests (for two groups meeting the normal distribution criteria) or Wilcoxon test (for two groups without normal distribution) according to the Shapiro–Wilk normality test. Comparisons for more than two groups were calculated using one-way analysis of variance (ANOVA) with Tukey's correction for multiple

comparisons (for three or more groups meeting the normal distribution criteria) or Kruskal–Wallis test with Dunn's correction for multiple comparisons (for three or more groups without normal distribution) according to the Shapiro–Wilk normality test. When comparing at least three distinct populations within the same mouse, comparisons were calculated using repeated measures (RM) one-way ANOVA with Tukey's correction for multiple comparisons (for samples meeting the normal distribution criteria) or Friedman test with Dunn's correction for multiple comparisons (for at least three groups without normal distribution) according to the Shapiro–Wilk normality test.

The statistical significance is represented as follows:  $*P < 0.05$ ,  $**0.05 < P < 0.01$ ;  $***0.01 < P < 0.001$ ,  $****P < 0.001$ .

## Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

## Data availability

All data supporting the findings of this study are available within the Article and its Supplementary Information. The scRNA-seq dataset reanalyzed is publicly available (Single Cell Portal; accession number SCP490)<sup>5</sup>. The RNA-seq dataset generated during the current study is available in the Gene Expression Omnibus repository (GSE279926). The rest of the data were originally generated.

## References

- Franceschi, C. & Campisi, J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. *J. Gerontol. A* **69**, S4–S9 (2014).
- Ferrucci, L. & Fabbri, E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. *Nat. Rev. Cardiol.* **15**, 505–522 (2018).
- Goronzy, J. J. & Weyand, C. M. Immune aging and autoimmunity. *Cell. Mol. Life Sci.* **69**, 1615–1623 (2012).
- Carrasco, E. et al. The role of T cells in age-related diseases. *Nat. Rev. Immunol.* **22**, 97–111 (2022).
- Elyahu, Y. et al. Aging promotes reorganization of the CD4 T cell landscape toward extreme regulatory and effector phenotypes. *Sci. Adv.* **5**, eaaw8330 (2019).
- Sakaguchi, S., Yamaguchi, T., Nomura, T. & Ono, M. Regulatory T cells and immune tolerance. *Cell* **133**, 775–787 (2008).
- Sharma, S., Dominguez, A. L. & Lustgarten, J. High accumulation of T regulatory cells prevents the activation of immune responses in aged animals. *J. Immunol.* **177**, 8348–8355 (2006).
- Trujillo-Vargas, C. M. et al. Immune phenotype of the CD4<sup>+</sup> T cells in the aged lymphoid organs and lacrimal glands. *GeroScience* **44**, 2105–2128 (2022).
- Soto-Herederó, G., Gómez de las Heras, M. M., Escrig-Larena, J. I. & Mittelbrunn, M. Extremely differentiated T cell subsets contribute to tissue deterioration during aging. *Annu. Rev. Immunol.* **41**, 181–205 (2023).
- Lorenzo, E. C. et al. Senescence-induced changes in CD4 T cell differentiation can be alleviated by treatment with senolytics. *Aging Cell* **21**, e13525 (2022).
- Kuswanto, W. et al. Poor repair of skeletal muscle in aging mice reflects a defect in local, interleukin-33-dependent accumulation of regulatory T cells. *Immunity* **44**, 355–367 (2016).
- Tsaknaris, L. et al. Functional assay for human CD4<sup>+</sup>CD25<sup>+</sup> Treg cells reveals an age-dependent loss of suppressive activity. *J. Neurosci. Res.* **74**, 296–308 (2003).
- Raynor, J. et al. IL-15 fosters age-driven regulatory T cell accrual in the face of declining IL-2 levels. *Front. Immunol.* **4**, 161 (2013).
- Lages, C. S. et al. Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation. *J. Immunol.* **181**, 1835–1848 (2008).
- Raynor, J. et al. IL-6 and ICOS antagonize Bim and promote regulatory T cell accrual with age. *J. Immunol.* **195**, 944–952 (2015).
- Morales-Nebreda, L. et al. Aging imparts cell-autonomous dysfunction to regulatory T cells during recovery from influenza pneumonia. *JCI Insight* **6**, e141690 (2021).
- Overacre-Delgoffe, A. E. et al. Interferon- $\gamma$  drives Treg fragility to promote anti-tumor immunity. *Cell* **169**, 1130–1141 (2017).
- Zagorulya, M. et al. Tissue-specific abundance of interferon- $\gamma$  drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer. *Immunity* **56**, 386–405 (2023).
- Henson, S. M. et al. KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8<sup>+</sup> T cells. *Blood* **113**, 6619–6628 (2009).
- Joshi, N. S. et al. Inflammation directs memory precursor and short-lived effector CD8<sup>+</sup> T cell fates via the graded expression of T-bet transcription factor. *Immunity* **27**, 281–295 (2007).
- Henson, S. M. & Akbar, A. N. KLRG1—more than a marker for T cell senescence. *Age* **31**, 285–291 (2009).
- Voehringer, D. et al. Viral infections induce abundant numbers of senescent CD8 T cells. *J. Immunol.* **167**, 4838–4843 (2001).
- Schwartzkopff, S. et al. Tumor-associated E-cadherin mutations affect binding to the killer cell lectin-like receptor G1 in humans. *J. Immunol.* **179**, 1022–1029 (2007).
- Li, L., Wan, S., Tao, K., Wang, G. & Zhao, E. KLRG1 restricts memory T cell antitumor immunity. *Oncotarget* **7**, 61670–61678 (2016).
- Ramello, M. C. et al. Polyfunctional KLRG1<sup>+</sup>CD57<sup>+</sup> senescent CD4<sup>+</sup> T cells infiltrate tumors and are expanded in peripheral blood from breast cancer patients. *Front. Immunol.* **12**, 713132 (2021).
- Cheng, G. et al. IL-2 receptor signaling is essential for the development of Klrp1<sup>+</sup> terminally differentiated T regulatory cells. *J. Immunol.* **189**, 1780–1791 (2012).
- López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. The hallmarks of aging. *Cell* **153**, 1194–1217 (2013).
- Ron-Harel, N. et al. Defective respiration and one-carbon metabolism contribute to impaired naïve T cell activation in aged mice. *Proc. Natl Acad. Sci. USA* **115**, 13347–13352 (2018).
- Bektas, A. et al. Age-associated changes in human CD4<sup>+</sup> T cells point to mitochondrial dysfunction consequent to impaired autophagy. *Aging* **11**, 9234–9263 (2019).
- Steinert, E. M., Vasan, K. & Chandel, N. S. Mitochondrial metabolism regulation of T cell-mediated immunity. *Annu. Rev. Immunol.* **39**, 395–416 (2021).
- Velarde, M. C., Flynn, J. M., Day, N. U., Melov, S. & Campisi, J. Mitochondrial oxidative stress caused by Sod2 deficiency promotes cellular senescence and aging phenotypes in the skin. *Aging* **4**, 3–12 (2012).
- Wiley, C. D. et al. Mitochondrial dysfunction induces senescence with a distinct secretory phenotype. *Cell Metab.* **23**, 303–314 (2016).
- Michalek, R. D. et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4<sup>+</sup> T cell subsets. *J. Immunol.* **186**, 3299–3303 (2011).
- Chapman, N. M. et al. mTOR coordinates transcriptional programs and mitochondrial metabolism of activated Treg subsets to protect tissue homeostasis. *Nat. Commun.* **9**, 2095 (2018).
- Weinberg, S. E. et al. Mitochondrial complex III is essential for suppressive function of regulatory T cells. *Nature* **565**, 495–499 (2019).
- Venditti, P., Di Stefano, L. & Di Meo, S. Mitochondrial metabolism of reactive oxygen species. *Mitochondrion* **13**, 71–82 (2013).
- Mittelbrunn, M. & Kroemer, G. Hallmarks of T cell aging. *Nat. Immunol.* **22**, 687–698 (2021).

38. Mogilenko, D. A. et al. Comprehensive profiling of an aging immune system reveals clonal GZMK<sup>+</sup> CD8<sup>+</sup> T cells as conserved hallmark of inflammaging. *Immunity* **54**, 99–115 (2021).
39. Wang, Y., Su, M. A. & Wan, Y. Y. An essential role of the transcription factor GATA-3 for the function of regulatory T cells. *Immunity* **35**, 337–348 (2011).
40. Wohlfert, E. A. et al. GATA3 controls Foxp3<sup>+</sup> regulatory T cell fate during inflammation in mice. *J. Clin. Invest.* **121**, 4503–4515 (2011).
41. Schiering, C. et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. *Nature* **513**, 564–568 (2014).
42. Siede, J. et al. IL-33 receptor-expressing regulatory T cells are highly activated, Th2 biased and suppress CD4 T cell proliferation through IL-10 and TGFβ release. *PLoS ONE* **11**, e0161507 (2016).
43. Boyman, O., Kovar, M., Rubinstein, M. P., Surh, C. D. & Sprent, J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. *Science* **311**, 1924–1927 (2006).
44. Sun, L. et al. Aged regulatory T cells protect from autoimmune inflammation despite reduced STAT3 activation and decreased constraint of IL-17 producing T cells. *Aging Cell* **11**, 509–519 (2012).
45. Garg, S. K. et al. Aging is associated with increased regulatory T-cell function. *Aging Cell* **13**, 441–448 (2014).
46. Zhao, L. et al. Changes of CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> regulatory T cells in aged Balb/c mice. *J. Leukoc. Biol.* **81**, 1386–1394 (2007).
47. Hwang, K.-A., Kim, H.-R. & Kang, I. Aging and human CD4<sup>+</sup> regulatory T cells. *Mech. Ageing Dev.* **130**, 509–517 (2009).
48. Delacher, M. et al. Precursors for nonlymphoid-tissue Treg cells reside in secondary lymphoid organs and are programmed by the transcription factor BATF. *Immunity* **52**, 295–312 (2020).
49. Beppu, L. Y. et al. Tregs facilitate obesity and insulin resistance via a Blimp-1/IL-10 axis. *JCI Insight* **6**, e140644 (2021).
50. Tauro, S., Nguyen, P., Li, B. & Geiger, T. L. Diversification and senescence of Foxp3<sup>+</sup> regulatory T cells during experimental autoimmune encephalomyelitis. *Eur. J. Immunol.* **43**, 1195–1207 (2013).
51. Hadis, U. et al. Intestinal tolerance requires gut homing and expansion of Foxp3<sup>+</sup> regulatory T cells in the lamina propria. *Immunity* **34**, 237–246 (2011).
52. Cebula, A. et al. Thymus-derived regulatory T cells contribute to tolerance to commensal microbiota. *Nature* **497**, 258–262 (2013).
53. Kaur, H., Kaur, G. & Ali, S. A. IL-33's role in the gut immune system: a comprehensive review of its crosstalk and regulation. *Life Sci.* **327**, 121868 (2023).
54. Goldberg, E. L. et al. IL-33 causes thermogenic failure in aging by expanding dysfunctional adipose ILC2. *Cell Metab.* **33**, 2277–2287 (2021).
55. Xu, L. et al. IL-33 induces thymic involution-associated naive T cell aging and impairs host control of severe infection. *Nat. Commun.* **13**, 6881 (2022).
56. Monzel, A. S., Enríquez, J. A. & Picard, M. Multifaceted mitochondria: moving mitochondrial science beyond function and dysfunction. *Nat. Metab.* **5**, 546–562 (2023).
57. Yu, Y.-R. et al. Disturbed mitochondrial dynamics in CD8<sup>+</sup> TILs reinforce T cell exhaustion. *Nat. Immunol.* **21**, 1540–1551 (2020).
58. Monteiro, L., de, B., Davanzo, G. G., de Aguiar, C. F. & Moraes-Vieira, P. M. M. Using flow cytometry for mitochondrial assays. *MethodsX* **7**, 100938 (2020).
59. Montes de Oca, M. et al. IL-27 signalling regulates glycolysis in Th1 cells to limit immunopathology during infection. *PLoS Pathog.* **16**, e1008994 (2020).
60. Chen, P.-M. et al. CD38 reduces mitochondrial fitness and cytotoxic T cell response against viral infection in lupus patients by suppressing mitophagy. *Sci. Adv.* **8**, eabo4271 (2022).
61. Konjar, Š. et al. Mitochondria maintain controlled activation state of epithelial-resident T lymphocytes. *Sci. Immunol.* **3**, eaan2543 (2018).
62. Kowaltowski, A. J. & Abdulkader, F. How and when to measure mitochondrial inner membrane potentials. *Biophys. J.* **123**, 4150–4157 (2024).
63. Ding, C. et al. A T<sub>reg</sub>-specific long noncoding RNA maintains immune-metabolic homeostasis in aging liver. *Nat. Aging* **3**, 813–828 (2023).
64. Guo, Z. et al. DCAF1 regulates Treg senescence via the ROS axis during immunological aging. *J. Clin. Invest.* **130**, 5893–5908 (2020).
65. Sun, Z. & Hornung, V. cGAS–STING signaling. *Curr. Biol.* **32**, R730–R734 (2022).
66. Dou, Z. et al. Cytoplasmic chromatin triggers inflammation in senescence and cancer. *Nature* **550**, 402–406 (2017).
67. Linder, A. & Hornung, V. Inflammasomes in T cells. *J. Mol. Biol.* **434**, 167275 (2022).
68. Baixeli, F. et al. Mitochondrial respiration controls lysosomal function during inflammatory T cell responses. *Cell Metab.* **22**, 485–498 (2015).
69. Milanovic, M. et al. Senescence-associated reprogramming promotes cancer stemness. *Nature* **553**, 96–100 (2018).
70. Salinas-Saavedra, M. et al. Senescence-induced cellular reprogramming drives cnidarian whole-body regeneration. *Cell Rep.* **42**, 112687 (2023).
71. Burton, O. T. et al. The tissue-resident regulatory T cell pool is shaped by transient multi-tissue migration and a conserved residency program. *Immunity* **57**, 1586–1602 (2024).
72. Correia-Melo, C. et al. Mitochondria are required for pro-ageing features of the senescent phenotype. *EMBO J.* **35**, 724–742 (2016).
73. Vardhana, S. A. et al. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. *Nat. Immunol.* **21**, 1022–1033 (2020).
74. Scharping, N. E. et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. *Nat. Immunol.* **22**, 205–215 (2021).
75. Valle-Noguera, A., Gómez-Sánchez, M. J., Girard-Madoux, M. J. H. & Cruz-Adalia, A. Optimized protocol for characterization of mouse gut innate lymphoid cells. *Front. Immunol.* **11**, 563414 (2020).

## Acknowledgements

Funded by the European Union. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Council Executive Agency. Neither the European Union nor the granting authority can be held responsible for them. This study was supported by European Research Council grant ERC-2021-CoG 101044248-LetTBe, and the Y2020/BIO-6350 NutriSION-CM synergy grant from Comunidad de Madrid, Ministerio de Ciencia e Innovación, Spain (grants PID2022-141169OB-I00 and PID2022-138295OB-I00). GENYAL Clinical Trials Platform of IMDEA Alimentación led by A. Ramírez de Molina and R. Ramos Ruiz conducted the volunteer recruitment and human clinical trial. Flow cytometry of human samples was conducted by Flow Cytometry Unit, CNIC, being the cytometer part of the grant EQC2018-005009-P funded by MCIN/AEI/10.13039/501100011033 and by 'ERDF A way of making Europe'. G.S.-H. is supported by a FPI-UAM grant (Universidad Autónoma de Madrid). E.G.-R. was funded by a Juan de la Cierva grant (IJC2018-036850-I; Universidad Autónoma de Madrid). M.G. and J.I.E.-L. are supported by FPU grants (FPU19/02576 and FPU20/04066, respectively), both from Ministerio de Ciencia, Innovación y Universidades (Spain). E.C. is supported by SI4/PJI/2024-00166 from Comunidad de Madrid and UAM (Spain). S.D.-P. was funded by a PIPF grant (PIPF-2022/SAL-GL-25208), from Comunidad de Madrid (Spain). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.



## Author contributions

G.S.-H., E.G.-R., E.C. and M.M. set up the research project and designed the experiments. G.S.-H., E.G.-R., E.C., J.I.E.-L., M.M.G., S.D.P., I.F.Q. and E.M.B. conducted most of the experiments and acquired the data. M.J.R. performed and analyzed the data in Fig. 1f,g. V.Z. provided technical and scientific support. C.M.F.-D. and M.B.A.-F. performed the experiments and analyzed the data in Fig. 8 under the supervision of A.R. A.F.A., D.A., S.J., A.d.S., F.S.-C. and C.T. performed bioinformatic analysis. G.S.-H. assembled the figures. G.S.-H. and M.M. wrote the manuscript. M.M. obtained financial support and provided supervision.

## Competing interests

The authors declare no competing interests.

## Additional information

**Extended data** is available for this paper at <https://doi.org/10.1038/s43587-025-00855-9>.

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s43587-025-00855-9>.

**Correspondence and requests for materials** should be addressed to María Mittelbrunn.

**Peer review information** *Nature Aging* thanks Jorg Goronzy and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.


**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.


© The Author(s) 2025

<sup>1</sup>Departamento de Biología Molecular, Facultad de Ciencias, Centro de Biología Molecular 'Severo Ochoa', Universidad Autónoma de Madrid, Madrid, Spain. <sup>2</sup>Consejo Superior de Investigaciones Científicas, Centro de Biología Molecular 'Severo Ochoa', Universidad Autónoma de Madrid, Madrid, Spain. <sup>3</sup>Departamento de Biología, Facultad de Ciencias, Centro de Biología Molecular 'Severo Ochoa', Universidad Autónoma de Madrid, Madrid, Spain. <sup>4</sup>Servicio de Microscopía Electrónica, Centro de Biología Molecular 'Severo Ochoa', Universidad Autónoma de Madrid, Madrid, Spain. <sup>5</sup>IMDEA Food Institute, CEI UAM+CSIC, Madrid, Spain. <sup>6</sup>Centro Nacional de Investigaciones Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain. <sup>7</sup>Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch sur-Alzette, Luxembourg. <sup>8</sup>CIC bioGUNE-BRTA (Basque Research and Technology Alliance), Bizkaia Technology Park, Derio, Spain. <sup>9</sup>IKERBASQUE, Basque Foundation for Science, Bilbao, Spain. ✉ e-mail: [mmittelbrunn@cbm.csic.es](mailto:mmittelbrunn@cbm.csic.es)




**Extended Data Fig. 1 | CD4<sup>+</sup> T cells progressively lose mitochondrial mass and mitochondrial membrane potential during aging.** (a) Representative plots of mitochondrial mass and mitochondrial membrane potential analyzed by flow cytometry in CD4<sup>+</sup> T cells treated or not treated with oligomycin. Cells were gated as MtG<sup>hi</sup>MtDR<sup>hi</sup>, MtG<sup>hi</sup>MtDR<sup>lo</sup> and MtG<sup>lo</sup>MtDR<sup>lo</sup>. Mitochondrial mass analyzed as gMFI of MtG (b) and mitochondrial membrane potential analyzed as gMFI of MtDR (c) measured by flow cytometry in circulating CD4<sup>+</sup> T cells from mice from 2- (n = 5), 9- (n = 5), 13- (n = 5) and 21- (n = 6) month-old mice. (d) Representative flow cytometry plots and quantifications of the simultaneous analysis of MtG and TMRM in splenic CD4<sup>+</sup> T cells from young (2-month-old, n = 5)

and old (21-month-old, n = 4) mice. (e) Quantification of the MtDR/MtG ratio in MtG<sup>hi</sup>MtDR<sup>hi</sup> and MtG<sup>lo</sup>MtDR<sup>lo</sup> CD4<sup>+</sup> T cells from mice at different ages (n = 6 mice per group). gMFI: Geometric Mean Fluorescence Intensity; MtG: Mitotracker Green; MtDR: Mitotracker DeepRed. Each dot represents an individual mouse. Data are presented as mean values  $\pm$  SEM. Statistical analysis was performed using one-way ANOVA with post hoc Tukey's correction (b), Kruskal-Wallis test with post hoc Dunn's correction (c), two-tailed Student's t test [(d): TMRM<sup>hi</sup>MtG<sup>hi</sup>; (e)] or two-tailed unpaired Welch's t test [(d): TMRM<sup>lo</sup>MtG<sup>lo</sup>] (b). \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ ; \*\*\*\* $P < 0.0001$ . Exact  $P$  values and additional statistical parameters can be found in the source data.



**Extended Data Fig. 2 | Identification of age-associated T cells by scRNAseq and by spectral flow cytometry.** (a) UMAP representation of CD4<sup>+</sup> T cells from young (left) and old mice (right) analyzed by scRNAseq (top) or spectral flow cytometry (bottom). (b) UMAP with clustering overlay showing the distribution of the different clusters of CD4<sup>+</sup> T cells identified by scRNAseq or by spectral flow cytometry: naive (blue), naive\_ISG15 (dark blue), rTregs (yellow), aTregs (orange), kTregs (red), TEM (light green), cytotoxic (brown) and exhausted (dark green) (n = 4 mice per group). (c) Percentage of circulating KLRG1<sup>+</sup> cells in CD4<sup>+</sup>


T cells from 2- (n = 6), 9- (n = 6), 13- (n = 5), 17- (n = 6) and 21- (n = 6) month-old mice assessed by flow cytometry. (d-e) Percentage of splenic KLRG1<sup>+</sup> cells in CD4<sup>+</sup>FOXP3<sup>+</sup>CD25<sup>+</sup> T cells (d) or in CD4<sup>+</sup> T cells (e) from 2- (n = 3), 9- (n = 4), 17- (n = 4) and 21- (n = 4) month-old mice. Each dot represents an individual mouse. Data are presented as mean values  $\pm$  SEM. Statistical analysis was performed using one-way ANOVA with post hoc Tukey's correction [(c), (d), (e)]. \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ ; \*\*\*\* $P < 0.0001$ . Exact  $P$  values and additional statistical parameters can be found in the source data.



**Extended Data Fig. 3 | Reanalysis of publicly available scRNAseq data identifies kTregs with a pro-inflammatory signature.** (a) UMAP representation and clustering of a new analysis of publicly available scRNAseq data from CD4<sup>+</sup> T cells from young and old mice. Clusters are colored as naïve (blue), rTregs (yellow), aTregs (orange), kTregs (red), T<sub>EM</sub> (light green), cytotoxic (brown) and exhausted (dark green). (b) Quantification of the percentage of kTreg cells in young and old mice (n = 4 mice per group). (c) Comparative expression of genes


related to Treg function in aTreg and kTreg (n = 4 mice per group). (d) Violin plots showing the expression of several pro-inflammatory markers in each cluster of CD4<sup>+</sup> T cells (n = 4 mice per group). Each dot represents an individual mouse. Box-and-whisker plots show the median, the maximum, the minimum and 25th and 75th percentiles. Statistical analysis was performed using two-tailed unpaired Welch's t test (b). Exact P values and additional statistical parameters can be found in the source data.






**Extended Data Fig. 4 | Analysis of the expression of different transcription factors in the Treg subsets.** Representative histograms and quantifications of the expression of different transcription factors by flow cytometry in splenic rTreg (yellow), aTreg (orange) and kTregs (red) from young (2-month-old) mice (n = 6 mice per group) measured as gMFI. gMFI values are relative to the MFI in

rTregs (n = 6 per group). gMFI: Geometric Mean Fluorescence Intensity. Each dot represents an individual mouse. Data are presented as mean values  $\pm$  SEM. Statistical analysis was performed using Friedman test with post hoc Dunn's correction. \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ ; \*\*\*\* $P < 0.0001$ . Exact  $P$  values and additional statistical parameters can be found in the source data.



**Extended Data Fig. 5 | KLRG1<sup>+</sup> Tregs show a pro-inflammatory phenotype and induce inflammation.** (a–b) *In vitro* assessment of the suppressive activity of KLRG1<sup>+</sup> Tregs. KLRG1<sup>+</sup> or KLRG1<sup>+</sup> Tregs were sorted from old (22-month-old) and co-cultured with CD45.1 naïve CD4<sup>+</sup> T responder cells labelled with CellTrace Violet at 2:1 ratio (2 naïve:1 Treg) for 72 h in the presence of α-CD3/α-CD28 (n = 3 mice). (a) Representative histogram of the CellTrace Violet signal measured by flow cytometry in CD45.1 CD4<sup>+</sup> T conventional responder cells after 72 h of culture. (b) Quantification of the capacity of KLRG1<sup>+</sup> and KLRG1<sup>+</sup> Treg cells to suppress the proliferation of CD45.1 CD4<sup>+</sup> responder T cells. The percentage of suppression was determined as: 100 – (% of proliferating cells with Tregs) / (% of proliferating cells without Tregs). (c) Representative histograms and quantifications of the expression of different cytokines by flow cytometry in splenic rTreg (yellow), aTreg (orange) and kTregs (red) from old (21-month-old) mice measured as gMFI. gMFI values are relative to the MFI in rTregs (n = 6 mice per group). (d–e) Analysis of the secretion of different cytokines by the Treg subsets in activating conditions using multiplex. Treg subsets were sorted from young mice injected with IL-2 + IL-33 and incubated during 24 h in the presence of α-CD3/α-CD28 before the assay (n = 3 mice). (d) Heatmap and statistical

comparisons of the secretion of different cytokines by rTreg, aTreg and kTregs. Heatmap values are relative to the maximum of each cytokine. (e) Quantification of IL-10, IL-6, GM-CSF and CXCL2 secreted by activated rTreg, aTreg and kTregs. (f–h) *In vivo* assessment of the pro-inflammatory activity of KLRG1<sup>+</sup> Tregs: CD3ε<sup>-/-</sup> T cell deficient mice were injected with splenic KLRG1<sup>+</sup> or KLRG1<sup>+</sup> Tregs isolated from young mice injected with IL-2 + IL-33. The mice were analyzed four months after the adoptive transfer (n = 3 mice per group). (f) Schematic diagram depicting the adoptive transfer of kTregs. (g) Spleen weight from CD3ε<sup>-/-</sup> mice non-injected or injected with KLRG1<sup>+</sup> or KLRG1<sup>+</sup> T cells. (h) Quantification of the percentage of circulating neutrophils or basophils in CD3ε<sup>-/-</sup> mice non-injected or injected with KLRG1<sup>+</sup> or KLRG1<sup>+</sup> T cells. gMFI: Geometric Mean Fluorescence Intensity. Each dot represents an individual mouse. Data are presented as mean values ± SEM. Statistical analysis was performed using two-tailed unpaired Student's t test (b), Friedman test with post hoc Dunn's correction [(d), (e); IL-6], RM one-way ANOVA with post hoc Tukey's correction [(d); (e); IL10, GM-CSF, CXCL2] or ANOVA with post hoc Tukey's correction [(g), (h)]. \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001; \*\*\*\*P < 0.0001. Exact P values and additional statistical parameters can be found in the source data.



**Extended Data Fig. 6 | Gating strategy to identify KLRG1<sup>+</sup> Tregs in human PBMCs.** Gating strategy followed to identify KLRG1<sup>+</sup> Tregs (CD45<sup>+</sup>CD3<sup>+</sup>CD4<sup>+</sup>CD8<sup>-</sup>CD25<sup>+</sup>IL7R KLRG1<sup>+</sup>) in human PBMCs.

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

|                                     |  |
|-------------------------------------|--|
| n/a                                 | Confirmed  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> The exact sample size ( <i>n</i> ) for each experimental group/condition, given as a discrete number and unit of measurement   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> The statistical test(s) used AND whether they are one- or two-sided<br><i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A description of all covariates tested   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted<br><i>Give P values as exact values whenever suitable.</i>                     |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings  |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes  |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i> ), indicating how they were calculated  |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

|                 |   |
|-----------------|---|
| Data collection | Flow cytometry data were collected with commercial softwares. SpectroFlo was used for acquisition of mouse samples in Aurora flow cytometers (Cytex Biosciences). FACS Diva was used for acquisition of human samples data in a BD FACSymphony A5 SORP flow cytometer (BD Biosciences)  |
| Data analysis   | <p>Flow Cytometry</p> <p>Flow cytometry data were analyzed using the FlowJoTM v.10 software (BD Biosciences).<br/>For multiparametric analysis, dimensional reduction and clustering analysis of flow cytometry data was done using OMIQ (Dotmatics).</p> <p>Electron microscopy</p> <p>Images were visualized and quantified with FIJI software (NIH).</p> <p>scRNAseq</p> <p>scRNAseq data was extracted from a previously published work 5 and reanalyzed with the Seurat package v4.2.0 in R v4.1.3. Variable genes were identified with the FindVariablesFeatures function across the range of expression values and used to perform a principal component analyses (PCA) with the RunPCA function. Clustering was performed with the FindClusters function with the Leiden algorithm and the first 20 principal components. Clusters identification was done with the FindMarkers function in each subset with a minimum log fold change of 0.25 and a P-value &lt;10-3. kTreg cluster was separated by using FindSubCluster function in the aTreg cluster and then identified with the FindMarkers function.</p> <p>RNAseq</p> <p>Fastq files quality check was performed using FastQC v0.11.9. RNA-sequencing reads were mapped to the Mus musculus reference genome,</p> |



GRCm39, using Hisat2 v2.2.1 software. Reads were then preprocessed with SAMtools v1.13 to transform Sequence Alignment/Map files into Binary Alignment/Map files and sorted. The number of reads covered by each gene is calculated by HTSeq-Count v1.99.2. Downstream data analysis was performed with R v4.4.1. DEG analysis was performed using DESeq2 v1.44.0. Genes with  $p < 0.05$  and  $|\log_2FC| > \log_2(1.5)$  were determined to show statistically significant differences in group comparison. Over-Representation Analysis (ORA) and Gene Set Enrichment Analysis (GSEA) were performed using clusterProfiler v4.12.0 package in GO, KEGG, WikiPathways, Reactome and the Hallmarks of the Molecular signatures database. PCA plots, Volcano plot and heatmaps were visualized by using ggplot2 v3.5.1. and heatmap v1.0.12, respectively.

#### Statistic analysis

Data analysis and representation was performed with GraphPad Prism v9.1.1 (Dotmatics).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

## Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

All data supporting the findings of this study are available within the paper and its Supplementary Information.

The scRNAseq data used in Extended Figure 2 and Extended Figure 3 were collected from "Aging promotes reorganization of the CD4 T cell landscape toward extreme regulatory and effector phenotypes" Elyahu et al. 2019, Science Advances (doi: 10.1126/sciadv.aaw8330).

RNAseq data is available and can be found under GEO accession number GSE279926.

The rest of the data were originally generated.

## Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

#### Reporting on sex and gender

Consent was obtained to communicate and share dissociated data at the individual level.

Information regarding the sex of the participants was collected. Sex was determined based on self-reporting by the volunteers.

No information regarding the gender of the participants was collected.

A total of 14 males and 28 females participated in the study within the young population subgroup, and a total of 28 males and 47 females within the senior population subgroup.

The results shown in the study apply to both sexes. The experimental groups have been defined by the age or the participants and no sex- and gender-based analyses have been performed.

#### Reporting on race, ethnicity, or other socially relevant groupings

Information on ethnicity was self-reported by study participants. All volunteers (100%) in the study self-reported their ethnicity as European Mediterranean.

This information was collected with the sole purpose of understanding the possible genetic variability of the population, local adaptations and cultural influences. In this research no categorization by race, ethnicity, or other socially relevant groupings was performed.

#### Population characteristics

In accordance with the objectives of the study, volunteers were recruited according to their age. Peripheral blood samples were collected from a total of 144 volunteers belonging to two different population groups, whose inclusion criteria were:

- Young healthy population (n=78): Healthy volunteers aged between 18 and 25 years.
- Senior population (n=66): Volunteers over 55 years of age.

Exclusion criteria were common for both study groups and included: decreased cognitive function, pregnancy or breastfeeding, severe chronic health conditions (chronic kidney/liver/heart disease...), immunodeficiencies and autoimmune diseases, and immunosuppressive or psychotropic pharmacological treatment.

#### Recruitment

Volunteers recruitment was performed through the GENYAL Clinical Trials Platform of IMDEA Alimentación (Madrid, Spain), which has a database of more than 2,000 active volunteers, as well as through the dissemination of recruitment posters on social networks of the IMDEA Institute. All patients were clearly informed about the study methodology and provided written informed consent.

#### Ethics oversight

All procedures involving human participants in this research were conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all human research participants. The Ethics committee approving this research was the Research Ethics Committee of the IMDEA Food Foundation. The approval codes for both clinical research protocols were IMD code: PI-052 (young population) and IMD code: PI-052 (senior population).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

# Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

|                 |   |
|-----------------|---|
| Sample size     | In all the experiments of this study, no statistical method was used to predetermine sample size, but a minimum of four samples were used per experimental group and condition. Four individual samples were considered as the minimum to have enough information for statistical tests and still reduce the number of animals used. In addition, most of the experiments were performed with 5 or 6 mice because they were initially caged together.                   |
| Data exclusions | Mice with signs of unhealthy aging (dermatitis, tumours) were removed before performing the experiments. When the experimental groups had more than 4 samples, outliers were identified by the ROUT method (5%) and removed. Since many analytical techniques rely on measures of central tendency like mean, outliers with extreme values can unduly influence calculations. The exclusion criteria were pre-established and applied to all the experiments performed. |
| Replication     | Representative plots and graphs summarize results of at least two independent experiments. All attempts at replication were successful.   |
| Randomization   | Mice were caged together and grouped by their date of birth for this study. Human samples were grouped solely based on age.   |
| Blinding        | In this study, experiments and data collection were primarily conducted in a no-blinded manner because the appearance of the animal is a strong indicator of its age and therefore its experimental group. Human samples were blinded for their analysis. Human samples were anonymized during collection and analyzed. Deanonimization and assignment to experimental groups were performed after analysis.  |

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

|                                     |   |
|-------------------------------------|---|
| n/a                                 | Involved in the study   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> Antibodies                  |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Eukaryotic cell lines                  |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Palaeontology and archaeology          |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> Animals and other organisms |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Clinical data                          |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Dual use research of concern           |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Plants                                 |

### Methods

|                                     |  |
|-------------------------------------|--|
| n/a                                 | Involved in the study                              |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> ChIP-seq                  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> Flow cytometry |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> MRI-based neuroimaging    |

## Antibodies

Antibodies used

Antibodies for mouse samples:

| Antibody         | Fluorochrome    | Clone      | Supplier       | Dilution | Catalog    |
|------------------|-----------------|------------|----------------|----------|------------|
| 1. CD38          | Pacific Blue    | 90         | Biolegend      | 1:500    | 102720     |
| 2. TIM3          | BV480           | 5D12/TIM-3 | BD Biosciences | 1:200    | 747618     |
| 3. CD244.2 (2B4) | BV510           | 2B4        | BD Biosciences | 1:200    | 740115     |
| 4. CD44          | BV570           | IM7        | Biolegend      | 1:200    | 103037     |
| 5. CD69          | BV650           | H1.2F3     | Biolegend      | 1:100    | 104541     |
| 6. CD62L         | BV711           | MEL-14     | Biolegend      | 1:400    | 104445     |
| 7. CD95          | BV750           | Jo2        | BD Biosciences | 1:100    | 747413     |
| 8. KLRG1         | BV785           | 2F1        | Biolegend      | 1:200    | 138429     |
| 9. CD223 (LAG3)  | BB515           | C9B7W      | BD Biosciences | 1:200    | 566210     |
| 10. CD49d        | PerCP Cy5.5     | R1-2       | Biolegend      | 1:100    | 103619     |
| 11. PD1          | PerCP eFluor710 | J43        | ThermoFisher   | 1:200    | 46-9985-80 |
| 12. ST2          | PerCP eFluor710 | RMST2-33   | ThermoFisher   | 1:200    | 46-9333-82 |
| 13. NKG2A        | PE              | 16A11      | Biolegend      | 1:200    | 142804     |
| 14. NKG2D        | PE-Dazzle594    | CX5        | Biolegend      | 1:200    | 130214     |

|                     |                 |              |                |        |            |
|---------------------|-----------------|--------------|----------------|--------|------------|
| 15. CD25            | PE Cy5          | PC61         | Biolegend      | 1:400  | 102007     |
| 16. CD8             | PE Fire700      | 53-6.7       | Biolegend      | 1:1000 | 100792     |
| 17. CD28            | APC             | E18          | Biolegend      | 1:50   | 122016     |
| 18. CD153           | R718            | RM153        | BD Biosciences | 1:200  | 751871     |
| 19. CD27            | APC Cy7         | LG.3A10      | Biolegend      | 1:400  | 124226     |
| 20. CD4             | APC Fire810     | Gk1.5        | Biolegend      | 1:1000 | 100480     |
| 21. IL-10           | Pacific Blue    | JES5-16E3    | Biolegend      | 1:100  | 505020     |
| 22. IL-17A          | PE              | TC11-18H10.1 | Biolegend      | 1:100  | 506904     |
| 23. TNF             | APC             | MP6-XT22     | Biolegend      | 1:100  | 506308     |
| 24. IFN- $\gamma$   | Spark NIR 685   | XMG1.2       | Biolegend      | 1:100  | 505861     |
| 25. MAF             | eFluor450       | sym0F1       | ThermoFisher   | 1:100  | 48-9855-41 |
| 26. FOXP3           | FITC            | FJK-165      | ThermoFisher   | 1:200  | 11-5773-82 |
| 27. ROR $\gamma$ t  | PE              | Q31-378      | BD Biosciences | 1:100  | 562607     |
| 28. T-BET           | AlexaFluor594   | 4B10         | Biolegend      | 1:100  | 644834     |
| 29. T-BET           | APC             | 4B10         | ThermoFisher   | 1:100  | 17-5825-82 |
| 30. TOX             | eFluor660       | TXRX10       | ThermoFisher   | 1:200  | 50-6502-80 |
| 31. $\gamma$ H2AX   |                 | 20E3         | CellSignaling  | 1:300  | 9718       |
| 32. P16             | -               | Polyclonal   | ThermoFisher   | 1:200  | PA5-119712 |
| 33. P21             | Alexa Fluor 647 | Polyclonal   | Abcam          | 1:400  | ab237265   |
| 34. Donkey a-Rabbit | Alexa Fluor 647 | Polyclonal   | ThermoFisher   | 1:500  | A-31573    |

## Antibodies for human samples:

| Antibody | Fluorochrome | Clone      | Supplier       | Dilution | Catalog |
|----------|--------------|------------|----------------|----------|---------|
| 1. CD8   | BUV496       | RPA-T8     | BD Biosciences | 1:100    | 612942  |
| 2. CD25  | BUV615       | 2A3        | BD Biosciences | 1:100    | 612996  |
| 3. CD19  | BUV661       | 1D3        | BD Biosciences | 1:100    | 612971  |
| 4. CD45  | BV510        | HI30       | BD Biosciences | 1:100    | 563204  |
| 5. CD4   | BV786        | SK3        | BD Biosciences | 1:100    | 664528  |
| 6. CD127 | PE           | HIL-7R-M21 | BD Biosciences | 1:100    | 561028  |
| 7. CD3   | APC          | HIT3a      | BD Biosciences | 1:100    | 555342  |
| 8. KLRG1 | APC Cy7      | 2F1/KLRG1  | Biolegend      | 1:100    | 138426  |

## Validation

All the antibodies used for flow cytometry are commercially available. they are extensively validated in the literature, and validation data are available on manufacturers's websites:

## Antibodies for mouse samples:

- <https://www.biolegend.com/en-us/products/pacific-blue-anti-mouse-cd38-antibody-6652>
- [https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/bv480-mouse-anti-mouse-cd366-tim-3.747618?tab=product\\_details](https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/bv480-mouse-anti-mouse-cd366-tim-3.747618?tab=product_details)
- [https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/bv510-mouse-anti-mouse-cd244-2.740115?tab=product\\_details](https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/bv510-mouse-anti-mouse-cd244-2.740115?tab=product_details)
- <https://www.biolegend.com/en-us/products/brilliant-violet-570-anti-mouse-human-cd44-antibody-7386>
- <https://www.biolegend.com/en-us/products/brilliant-violet-650-anti-mouse-cd69-antibody-13310>
- <https://www.biolegend.com/en-us/products/brilliant-violet-711-anti-mouse-cd62l-antibody-10317>
- [https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/bv750-hamster-anti-mouse-cd95-fas.747413?tab=product\\_details](https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/bv750-hamster-anti-mouse-cd95-fas.747413?tab=product_details)
- <https://www.biolegend.com/en-us/products/brilliant-violet-785-anti-mouse-human-klrg1-mafa-antibody-13682>
- [https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/bb515-rat-anti-mouse-cd223.566210?tab=product\\_details](https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/bb515-rat-anti-mouse-cd223.566210?tab=product_details)
- <https://www.biolegend.com/en-us/products/percp-cyanine5-5-anti-mouse-cd49d-antibody-9901>
- <https://www.thermofisher.com/antibody/product/CD279-PD-1-Antibody-clone-J43-Monoclonal/46-9985-80>
- <https://www.thermofisher.com/antibody/product/IL-33R-ST2-Antibody-clone-RMST2-33-Monoclonal/46-9333-82>
- <https://www.biolegend.com/en-us/products/pe-anti-mouse-cd159a-nkg2ab6-antibody-7543>
- <https://www.biolegend.com/en-us/products/pedazzle-594-anti-mouse-cd314-antibody-15542>
- <https://www.biolegend.com/en-us/products/pe-anti-mouse-cd25-antibody-424>
- <https://www.biolegend.com/en-us/products/pefire-700-anti-mouse-cd8a-antibody-19782>
- <https://www.biolegend.com/en-us/products/apc-anti-mouse-cd28-antibody-3781>
- [https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/r718-rat-anti-mouse-cd153.751871?tab=product\\_details](https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/r718-rat-anti-mouse-cd153.751871?tab=product_details)
- <https://www.biolegend.com/en-us/products/apc-cyanine7-anti-mouse-rat-human-cd27-antibody-11905>
- <https://www.biolegend.com/en-us/products/apc-fire-810-anti-mouse-cd4-antibody-19552>
- <https://www.biolegend.com/en-us/products/pacific-blue-anti-mouse-il-10-antibody-6145>
- <https://www.biolegend.com/en-us/products/pe-anti-mouse-il-17a-antibody-1633>
- <https://www.biolegend.com/en-us/products/apc-anti-mouse-tnf-alpha-antibody-975>
- <https://www.biolegend.com/en-us/products/spark-nir-685-anti-mouse-ifn-gamma-antibody-21051>
- <https://www.thermofisher.com/antibody/product/c-MAF-Antibody-clone-sym0F1-Monoclonal/48-9855-42>
- <https://www.thermofisher.com/antibody/product/FOXP3-Antibody-clone-FJK-16s-Monoclonal/11-5773-82>
- [https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/pe-mouse-anti-mouse-ror-t.562607?tab=product\\_details](https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/pe-mouse-anti-mouse-ror-t.562607?tab=product_details)
- <https://www.biolegend.com/en-us/products/alexa-fluor-594-anti-t-bet-antibody-15452>
- <https://www.thermofisher.com/antibody/product/T-bet-Antibody-clone-eBio4B10-4B10-Monoclonal/17-5825-82>
- <https://www.thermofisher.com/antibody/product/TOX-Antibody-clone-TXRX10-Monoclonal/50-6502-80>
- <https://www.cellsignal.com/products/primary-antibodies/phospho-histone-h2a-x-ser139-20e3-rabbit-mab/9718>
- <https://www.thermofisher.com/antibody/product/p16INK4a-Antibody-Polyclonal/PA5-119712>
- [https://www.abcam.com/en-us/products/primary-antibodies/alexa-fluor-647-p21-antibody-epr18021-ab237265?srsltid=AfmBOoqEnFws1c4Ge-gnZi\\_JoPu0MQXzrbnQu3EJmH9YuZMV0fVOZ2Ds](https://www.abcam.com/en-us/products/primary-antibodies/alexa-fluor-647-p21-antibody-epr18021-ab237265?srsltid=AfmBOoqEnFws1c4Ge-gnZi_JoPu0MQXzrbnQu3EJmH9YuZMV0fVOZ2Ds)



34. <https://www.thermofisher.com/antibody/product/Donkey-anti-Rabbit-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-31573>

Antibodies for human samples:

1. [https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/buv496-mouse-anti-human-cd8.612942?tab=product\\_details](https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/buv496-mouse-anti-human-cd8.612942?tab=product_details)
2. [https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/buv615-mouse-anti-human-cd25.612997?tab=product\\_details](https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/buv615-mouse-anti-human-cd25.612997?tab=product_details)
3. [https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/buv661-rat-anti-mouse-cd19.612971?tab=product\\_details](https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/buv661-rat-anti-mouse-cd19.612971?tab=product_details)
4. [https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/bv510-mouse-anti-human-cd45.563204?tab=product\\_details](https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/bv510-mouse-anti-human-cd45.563204?tab=product_details)
5. [https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/clinical-diagnostics/single-color-antibodies-asr-ivd-ce-ivd/cd4-sk3-bv786.664528?tab=product\\_details](https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/clinical-diagnostics/single-color-antibodies-asr-ivd-ce-ivd/cd4-sk3-bv786.664528?tab=product_details)
6. [https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/pe-mouse-anti-human-cd127.557938?tab=product\\_details](https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/pe-mouse-anti-human-cd127.557938?tab=product_details)
7. [https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/apc-mouse-anti-human-cd3.555342?tab=product\\_details](https://www.bdbiosciences.com/en-us/products/reagents/flow-cytometry-reagents/research-reagents/single-color-antibodies-ruo/apc-mouse-anti-human-cd3.555342?tab=product_details)
8. <https://www.biolegend.com/en-us/products/apc-cyanine7-anti-mouse-human-klrg1-mafa-antibody-12486>

## Animals and other research organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

### Laboratory animals

C57BL/6J HccRsd mice were used in this study. Mice were purchased from Envigo or generated at the Centro de Biología Molecular Severo Ochoa (Madrid, Spain) animal facilities.  
CD3e<sup>-/-</sup> mice (JAX stock #004177) and CD45.1 mice (JAX stock #002014) were generated at the Centro de Biología Molecular Severo Ochoa (Madrid, Spain) animal facilities.  
All mice required for this study were bred and aged in specific-pathogen-free conditions in the animal facility of Centro de Biología Molecular Severo Ochoa (Madrid, Spain). All mice were housed in ventilated cages within animal rooms maintained under a 12-12 light-dark cycle. Animal rooms were temperature and humidity controlled. Standard diet and water were available ad libitum. Ages of the mice are indicated in each figure.

### Wild animals

The study did not involve wild animals.

### Reporting on sex

Findings apply to both sexes of mice. Both male and female were used indiscriminately in the experiments. However, most of the experiments were performed with females due to the possibility to recage them.

### Field-collected samples

The study did not involve field-collected samples.

### Ethics oversight

All the procedures with animals were previously evaluated and approved (PROEX 287/16 and PROEX 52.1/23) by the Ethics committee on animal experimentation of the CBMSO, the authorized committee of the Spanish National Research Council or the Universidad Autónoma de Madrid and the regional government (Comunidad de Madrid). All mice were checked for any macroscopic abnormalities (according to the Jackson guide "AGED C57BL/6J MICE FOR RESEARCH STUDIES"). Mice were used at different ages: young (less than 4 months of age), adult (4 to 20 months of age) and old (over 20 months of age).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Flow Cytometry

### Plots

Confirm that:

- ☒ The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- ☒ The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- ☒ All plots are contour plots with outliers or pseudocolor plots.
- ☒ A numerical value for number of cells or percentage (with statistics) is provided.

### Methodology

#### Sample preparation

Mice were euthanized with CO<sub>2</sub> followed by perfusion with cold PBS. The indicated tissues were extracted and processed as specified:

Spleen and lymph nodes:

Lymph nodes were harvested from inguinal, mesenteric, cervical, and axillar areas. Spleen and lymph nodes were mashed and filtered through a 70-µm cell strainer. Red blood cells were removed using 5 ml of Erythrocyte lysis buffer (ammonium chloride 0.15 M, sodium bicarbonate 0.01 M, EDTA 0.0001 M) for 5 min. Cells were washed and counted.

Blood:

Blood was extracted from either the facial vein or the heart in living or euthanized mice, respectively. Red blood cells were removed using 5 ml of Erythrocyte lysis buffer for 5 min. Cells were washed and stained.

#### Colonic lamina propria:

T cells from colonic lamina propria were isolated as previously reported 67. Colon samples between the cecum and rectum were obtained and cleaned from fat and faeces. Tissues were cut longitudinally, washed with cold PBS and, then, cut transversally into 1cm-long fragments and mixed in pre-warmed 5 mM EDTA 14 mM Hepes 10% FBS PBS under shaking at 180 rpm for 30 min at 37°C. After washing with PBS, tissue pieces were then minced and mixed in pre-warmed 25 mM Hepes 10% FBS RPMI supplemented with 300 U/ml collagenase type VIII (Sigma, C2139) under shaking at 180 rpm for 45 min at 37°C. Digested tissue was filtered through a 70-µm cell strainer, washed with 5 mM EDTA 14 mM Hepes 10% FBS PBS and centrifuged at 650 x g for 5 min at room temperature (RT). To further enrich in leucocytes, supernatants were centrifuged in a 40%/70% Percoll gradient (Sigma, GE17-0891-01) at 750 x g for 20 min at RT without acceleration or brake. Isolated cells were washed with PBS and resuspended in 2% FBS RPMI for counting.

#### White adipose tissue:

Gonadal white adipose tissue was obtained from the mouse abdominal cavity and mixed in 2 mg/ml BSA 2% FBS RPMI supplemented with 2 mg/ml collagenase type II (Sigma, C6885) under shaking at 180 rpm for 40 min at 37°C. Digested tissues were vertically rested to separate fat from the aqueous phases, which were obtained using a 18G syringe. Then, cell suspensions were filtered through a 70-µm cell strainer and washed with 2% FBS RPMI. Finally, erythrocytes were removed by incubation with a lysis buffer for 5 min at 4°C, washed with 1 mM EDTA PBS and finally resuspended in 1 ml for counting.

#### Peyer's Patches:

Peyer's patches were harvested from the intestine and mashed into a 70-µm cell strainer. Cell suspension was centrifuged at 400 x g for 5 min at 4°C. Finally, cell pellets were resuspended in 1 ml of 2% FBS RPMI for counting.

#### Liver:

Liver was harvested and cut into pre-warmed 25 mM Hepes 10% FBS RPMI supplemented with 0.4 mg/ml collagenase type VIII (Sigma, C2139) under shaking at 180 rpm for 45 min at 37°C. Digested tissue was filtered through a 70-µm cell strainer and centrifuged at 350 x g for 5 min at 4°C. Red blood cells were removed using 5 ml of Erythrocyte lysis buffer for 5 min. Cells were washed and counted. To further enrich in leucocytes, supernatants were centrifuged in a 40%/70% Percoll gradient (Sigma, GE17-0891-01) at 1250 x g for 30 min at RT with acceleration on 6 and without brake. Isolated cells were washed with PBS and resuspended in ml 2% FBS RPMI for counting.

#### Bone marrow:

Femurs and tibias were collected. Cells from the bone marrow were obtained by centrifuging the bones at 6000 g for 1 minute. Red blood cells were removed using 5 ml of Erythrocyte lysis buffer (ammonium chloride 0.15 M, sodium bicarbonate 0.01 M, EDTA 0.0001 M) for 5 min. Cells were washed and counted.

To differentiate between live and dead, the cells were firstly stained with the Zombie NIR™ Fixable Viability Kit, the Zombie Yellow™ Fixable Viability Kit or the Ghost Dye™ Violet 540 for 20 min at 4°C. Then, the cells were washed with FACS staining buffer (PBS supplemented with 2% fetal bovine serum and 1 mM EDTA) and incubated with Fc receptor blocker purified rat anti-mouse anti-CD16/CD32 (BD Biosciences, 553142) for 20 min at 4°C. Cells were then incubated with primary antibodies for 20 min at 4°C and were washed twice with FACS staining buffer. For intracellular staining, after staining for membrane markers, the cells were fixed and permeabilized using the FOXP3/Transcription Factor Staining Kit (eBioscience) for 20 min at RT and darkness.

#### Human samples:

Human blood samples were collected by venipuncture in an overnight fasting state. 3 ml of blood were collected in TransFix/EDTA Vacuum Blood Collection Tubes (Cytomark, Buckingham, U.K.) and preserved until the day of staining and cell acquisition.

Cells were labelled by incubation with appropriate fluorescence-conjugated antibodies for 15 min at RT in the dark. Cells were then lysed with 2 mL of FACS lysing solution (BD Biosciences) for 10 minutes and centrifuged at 500 x g for 5 min at RT. Then, the cells were washed with 5 mL of PBS. The following antibodies were used for surface antigen staining.

Experiments with human samples were performed in a BD FACSymphony SORP flow cytometer (BD Biosciences). In order to generate comparable results among patients and over time, the photomultiplier voltages were adjusted to unlabeled lysed whole blood cells to obtain optimal photomultiplier tube voltages for the resolution of dim cell populations. The target values resulting of the optimization were used for subsequent calibrations to maintain instrument standardization. When possible, at least 40.000 events of CD4 population were acquired in order to reach the maximum Tregs events.

#### Instrument

Mouse samples were acquired in a 4-laser (Violet, blue, yellow-green, red) or a 5-laser Aurora analyzer (Cytek Biosciences). Human samples were acquired in a BD FACSymphony SORP flow cytometer (BD Biosciences).

#### Software

Data were analyzed with the FlowJo v10.5.3 software (BD Biosciences). Dimensional reduction and clustering analysis of flow cytometry data was done using OMIQ (Dotmatics).

#### Cell population abundance

For in vitro suppression and adoptive transfer experiments, Tregs KLRG1- and kTregs were sorted from the same mouse. Tregs were sorted from 5 young mice that had been previously injected with IL-2 + IL-33. Cells were gated as:

1. Lymphocytes in SSC-A / FSC-A plot
2. Alive cells as DAPI- in DAPI / FSC-A plot.
3. Single cells as a diagonal in FSC-H / FSC-A plot.
4. Tregs as CD4+CD25+ in CD25 / CD4 plot.
5. Tregs KLRG1- as KLRG1- in KLRG1 / FSC-A plot.
6. kTregs as KLRG1+ in KLRG1 / FSC-A plot.

For RNAseq, rTregs, aTregs and kTregs were sorted from the same mouse. Treg subsets were sorted from 4 young and 4 old mice. Cells were gated as:

1. Lymphocytes in SSC-A / FSC-A plot
2. Alive cells as DAPI- in DAPI / FSC-A plot.

3. Single cells as a diagonal in FSC-H / FSC-A plot.
4. Tregs as CD4+CD25+ in CD25 / CD4 plot.
5. rTreg as CD62L+ KLRG1- in KLRG1 / CD62L plot.
6. aTreg as CD62L- KLRG1- in KLRG1 / CD62L plot.
7. kTreg as CD62L- KLRG1+ in KLRG1 / CD62L plot.

After the sorting, the purity of sorted cells was checked in the same sorter. Purity was over 95% in all the sorted cells.

## Gating strategy

The gating strategy for mouse sample was:

1. Lymphocytes in FSC-A / SSC-A plot.
2. Single cells as a diagonal line in FSC-H / FSC-A plot.
3. Alive cells in a FSC-A / Viability marker.
4. CD4+ cells in CD4 / CD8 plot.

Boundaries between positive and negative populations were established above  $10^3$  and when the two populations were clearly defined.

The gating strategy for human samples is illustrated in Extended Data Figure 6. Briefly:

1. Single cells as a diagonal line in FSC-H / FSC-A plot.
2. Lymphocytes in FSC-A / SSC-A plot.
3. Leukocytes (CD45+ cells) in SSC-A / CD45 plot. CD45+ cells were gated.
4. Lymphocytes in SSC-A / FSC-H plot. FCS-Hlo cells were gated.
5. Lymphocytes in SSC-A / CD45 plot. CD45hi cells were gated.
6. T cells in CD3 / CD19 plot. CD3+CD19- cells were gated.
7. CD4+ T cells in CD4 / CD8 plot.
8. CD25+ CD127- cells in CD25 / CD127 plot.
9. KLRG1+ cells in CD4 / KLRG1 plot.

☒ Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.